x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2008

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

(Exact name of registrant as specified in its charter)

Delaware	20-2620798
(State of incorporation)	(I.R.S. Employer Identification No.)

15770 Laguna Canyon Road, Suite 150 Irvine, California	92618
(Address of principal executive offices)	(Zip code)

Registrant's telephone number, including area code: (949) 453-0150

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:	Name of each exchange on which registered:
Common Stock, $0.0001 Par Value Per Share	The Nasdaq Capital Market

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes o No x

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes o No x

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. x

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer o	Accelerated filer o
Non-accelerated filer o	Smaller reporting company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes o No x

The aggregate market value of the registrant's voting stock held by non-affiliates of the registrant (based on the closing price as reported on the Nasdaq Capital Market on June 30, 2008) was approximately $16.5 million. Shares of voting stock held by each officer and director and by each shareholder affiliated with a director have been excluded from this calculation because such persons may be deemed to be affiliates. This determination of officer or affiliate status is not necessarily a conclusive determination for other purposes. The number of outstanding shares of the registrant’s Common Stock as of March 27, 2009 was 21,076,134.

FORWARD-LOOKING STATEMENTS

In addition to historical information, this Annual Report on Form 10-K contains statements relating to future results of Alsius Corporation (including certain projections and business trends) that are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created by those sections. Our actual results may differ materially from those projected as a result of certain risks and uncertainties. These risks and uncertainties include those set forth herein and those detailed from time to time in our other Securities and Exchange Commission filings. These forward-looking statements are made only as of the date hereof, and we undertake no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as otherwise required by law.

ALSIUS CORPORATION

TABLE OF CONTENTS

		PAGE
PART I

Item 1.	Business	2
Item 1A.	Risk Factors	7
Item 1B.	Unresolved Staff Comments	20
Item 2.	Properties	20
Item 3.	Legal Proceedings	20
Item 4.	Submission of Matters to a Vote of Security Holders	20

PART II

Item 5.	Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	21
Item 6.	Selected Financial Data	22
Item 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	24
Item 7A.	Quantitative and Qualitative Disclosures About Market Risk	38
Item 8.	Financial Statements and Supplementary Data	39
Item 9.	Changes in and Disagreements With Accountants on Accounting and Financial Disclosure	68
Item 9A(T).	Controls and Procedures	68
Item 9B.	Other Information	68

PART III

Item 10.	Directors, Executive Officers and Corporate Governance	69
Item 11.	Executive Compensation	74
Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	86
Item 13.	Certain Relationships and Related Transactions, and Director Independence	87
Item 14.	Principal Accountant Fees and Services	87

PART IV

Item 15.	Exhibits and Financial Statement Schedules	89

PART I

Item 1.

Business

General

On June 21, 2007, Ithaka Acquisition Corp., a Delaware corporation (”Ithaka”), completed its acquisition of Alsius Corporation, a privately held California corporation (“Alsius Medical”), through a merger of a wholly owned subsidiary with and into Alsius Medical. Ithaka was a publicly traded blank check company formed in 2005 to acquire an unidentified operating business in the healthcare industry. In the merger, Alsius Medical became a wholly owned subsidiary of Ithaka, and Ithaka changed its name to Alsius Corporation. As a result, Alsius Corporation succeeded Ithaka as the reporting registrant for purposes of this report. Alsius Corporation is now a publicly traded Delaware holding company operating through its wholly owned subsidiary, Alsius Medical Corporation. Alsius Corporation and its operating subsidiary are referred to collectively as “Alsius,” “we,” “us,” and the “Company”. Alsius Corporation’s common stock trades on NASDAQ under the symbol “ALUS”. For accounting purposes, the merger was treated as a reverse acquisition with Alsius Medical being the accounting acquirer. Therefore, the Company’s historical financial statements reflect those of Alsius Medical, the operating subsidiary.

Alsius is a commercial-stage medical device company that develops, manufactures and sells proprietary, innovative products to precisely control patient temperature in hospital critical care settings. Controlling body temperature, through cooling and warming, is standard of care for patients in critical condition and those undergoing a variety of surgical procedures. As has been well documented, temperature management improves outcomes and reduces complications in patients being treated for a range of conditions such as cardiac arrest, stroke and head trauma, as well as during cardiothoracic surgery.

We market a comprehensive suite of catheter-based intravascular temperature management products that, based on management’s experience and knowledge of the industry and discussions with physicians, address an unmet clinical need for effective, accurate, easy-to-use and cost-effective control of body temperature in critical care patients. Our products consist of the CoolGard and Thermogard systems and five families of single-use catheters—Cool Line, Icy, Fortius, Quattro, and Solex. The CoolGard and Thermogard systems are computer-controlled temperature regulation systems that circulate cool or warm saline in a closed-loop circuit through balloons that surround our catheters. Our catheters are inserted into a major vein through a patient’s neck or groin and achieve rapid and precise temperature management through contact with the patient’s blood flow. A key feature of our catheters is their ability to function as central venous catheters, which are routinely used in the treatment of critically ill patients to administer drugs and fluids, draw blood and monitor blood pressure. Unlike conventional external temperature management products, such as cooling and warming blankets and ice packs, our intravascular products cool and warm the patient from the inside out, which we believe more effectively manages body temperature and allows caregivers easier access to administer patient care.

We operate in one reportable business segment through our operating subsidiary, Alsius Medical. See Note 12 to the Notes to Consolidated Financial Statements — Segment Reporting, for a summary of revenues by customer location for the years ended December 31, 2008, 2007 and 2006.

Our principal corporate office is located at 15770 Laguna Canyon Road, Suite 150, Irvine, CA 92618, and our main telephone number at that location is 949-453-0150. Our common stock trades on the Nasdaq Capital Market under the symbol ALUS.

Recent Developments

Asset Sale

On February 20, 2009, we announced that we signed an asset purchase agreement (the “Purchase Agreement”) with Zoll Circulation, Inc. (“Zoll”), a wholly owned subsidiary of ZOLL Medical Corporation (Nasdaq: ZOLL) whereby we will sell substantially all our assets, including those constituting our intravascular temperature management device business, to Zoll for a purchase price of $12.0 million in cash (the “Asset Sale”). In connection with the Asset Sale, Zoll placed an order with the Company to purchase approximately $3.0 million of finished product at cost. The closing of the Asset Sale is subject to customary closing conditions, and is expected to close as soon as possible in the second quarter of 2009. On February 25, 2009, we filed a current report on Form 8-K which summarized the principal terms of the Asset Sale and attached a copy of the Purchase Agreement in our filing.

The record holders of a majority of the outstanding shares of the Company’s common stock have executed a written consent to approve the Asset Sale. The Asset Sale is discussed in further detail in a draft information statement that we filed with the SEC. When the SEC review is complete, we will mail a definitive information statement (the "Information Statement") to our stockholders and, under applicable rules, can close the Asset Sale 20 days after the mailing.

Plan of Dissolution

On February 19, 2009, our Board also unanimously adopted a plan providing for the complete dissolution and liquidation of the Company (the “Plan of Dissolution”). The holders of a majority of the outstanding shares of our common stock have executed a written consent to adopt and approve the Plan of Dissolution.

Assuming, as expected, that the Asset Sale is consummated, we will file a certificate of dissolution with the Delaware Secretary of State to dissolve the Company as a legal entity, complete the liquidation of its remaining assets, and satisfy (or make provisions to satisfy) its remaining obligations.

Pursuant to the Plan of Dissolution, after payment or provision for all the known, unascertained or contingent debts, obligations and liabilities of the Company (including costs and expenses incurred and anticipated to be incurred in connection with the Asset Sale and liquidation of the Company), payment or distributions will be made to the holders of our common stock. The potential timing and amount of distributions is discussed below under Liquidating Distributions. In the unexpected event all distributions have not occurred within three years of filing of the certificate of dissolution, our remaining assets will be transferred to a liquidating trust for the benefit of our stockholders, and a liquidation trustee will be assigned to administer the assets, settle liabilities, and make distributions to stockholders if and when funds are legally available for distribution.

Following dissolution, we will change our name from “Alsius Corporation” to “ALUS Liquidation Corp.” and will cease conducting normal business operations, except as required to wind down our affairs. We will continue our corporate existence solely for the purpose of winding down and liquidating, including collecting accounts receivable, selling ancillary assets that Zoll may elect not to take, settling liabilities and making distributions to stockholders, and otherwise completing the liquidation of the Company. We will not be authorized to engage in any business activities other than these, thus limiting our exposure for business activities unrelated to the wind down and liquidation.

Liquidating Distributions

We anticipate that an initial distribution of liquidation proceeds will be made to our stockholders within 90 days after the closing of the Asset Sale. As we collect accounts receivable and pay off our outstanding liabilities, we will distribute additional liquidation proceeds, if any, to our stockholders as the Board or its authorized designees deem appropriate. A final $1 million will be held in trust for one year from the closing date of the Asset Sale to cover potential indemnity obligations to Zoll under the Purchase Agreement for the Asset Sale.

We estimate that we will ultimately distribute an aggregate of $7.6 million to our stockholders, or $0.34 per share of our common stock. However, the amounts to be distributed to stockholders may be less if we incur greater liabilities than anticipated in winding down our affairs and/or if we generate less revenue than anticipated through the closing of the Asset Sale. (Alternatively, it is possible that we could distribute more than currently estimated if liabilities are less than expected and/or revenues are greater than expected.) A key factor in maximizing potential distributions is the timing of the closing of the Asset Sale, which is subject to certain risks and uncertainties. To the extent the closing of the Asset Sale is delayed beyond April 2009, we anticipate incurring additional operating expenses of up to $1 million per month to operate the Company through closing.

Our current estimate of cash assets and liabilities, and net available funds to distribute to stockholders, that will be available following the sale of substantially all of our assets to Zoll is set forth more fully herein in Item 7: Management’s Discussion and Analysis of Financial Condition and Results of Operations," and was also discussed in the Information Statement filed with the SEC on March 27, 2009. Please see Item 7 for a more detailed discussion of our anticipated available funds and the significant liabilities which are currently difficult to predict. You should also read the risk factors herein regarding additional uncertainties that can reduce the amounts available for distribution to stockholders.

Strategy

Our goal has been to be the leading worldwide provider of medical products for temperature management in hospital critical care settings. The key elements of our strategy include:

Leverage our first mover advantage. Based on our experience in the acute care temperature management market, we believe we are the worldwide leader in sales of intravascular temperature management products which has enabled us to continue to set the industry standard for novel temperature management. We have an established sales, marketing, distribution and service infrastructure, which we intend to leverage to support our growth worldwide.

·	Drive adoption. We drive adoption of our products by promoting awareness among leading hospitals and critical care practitioners, including participating in clinical trials, training physicians and supporting the adoption of temperature management treatment guidelines.

Increase system installations and catheter use. Our goal has been to increase system installations at target hospitals and drive catheter use among existing customers. We have worked to increase sales through expansion of our U.S. direct sales force, and through our distributors in existing markets in Europe, Canada and Australia, and expand into China, Japan and other Asian countries.

·	Enhance existing products and develop new products. We improve the design of our current products and expand our pipeline of future products. We continually enhance our systems, software and catheters to deliver more effective and easier-to-use temperature management products.

Improve margins through scale and efficiency. We are focused on improving gross margins by lowering our raw material and manufacturing costs, and have sought to realize economies-of-scale as sales increase. Our intent has been to improve operating margins and gross margins through a combination of increased sales, as we penetrate worldwide markets for our products, implement cost reduction initiatives and absorb fixed and partially fixed costs through increased production levels.

Research and Development

We invest in research and development to enhance our CoolGard and Thermogard systems and family of catheters and develop new products, based on customer feedback and demand. We work closely with leading critical care physicians and nurses to better understand unmet needs and new applications in temperature management. Product enhancements may include increased system power to achieve faster cooling and warming, changes in catheter design to accommodate new applications as well as refinements that lower manufacturing costs. As of December 31, 2008, we had 21 full-time employees in the research and development group.

We incurred research and development expenses of $4.2 million, $3.9 million, and $2.9 million in 2008, 2007 and 2006, respectively.

Manufacturing

We lease approximately 27,000 square feet of space at our Irvine, California, headquarters. We design, manufacture and test our products at our headquarters, which is compliant with ISO and FDA standards. Product quality, cost reduction and inventory management are top priorities for our manufacturing operations. In connection with the Asset Sale to Zoll, we intend to vacate our facility and negotiate a lease termination with our landlord.

We are currently producing systems and catheters to support our sales through the closing of the Asset Sale, and to build inventory for Zoll to sell following the Asset Sale as agreed per the Purchase Agreement. We assemble the CoolGard and Thermogard systems and catheters from components and subassemblies that we purchase from outside sources. We have flexibility with our suppliers to adjust the number of components and subassemblies as well as the delivery schedules. Production requirements are based on sales forecasts. Lead times for components and subassemblies may vary significantly depending on the size of the order, time required to fabricate and test the components or subassemblies, specific supplier requirements and current market demand for the components and subassemblies. We seek to reduce the potential for disruption of supply by maintaining sufficient inventory and identifying additional suppliers, where possible. However, we currently purchase certain of our components and subassemblies from single source suppliers. If we lost a single-source supplier, we would need to qualify new suppliers, or to redesign components, which could cause delays in our manufacturing. To date, we have not experienced any significant delays in obtaining any components or subassemblies.

Customers, Marketing and Sales

We began selling our products in the United States in April 2004 and, as of December 31, 2008, had established a U.S. installed base of over 327 systems in 169 hospitals, of which 293 had been sold and 34 were under evaluation. We began building our current network of independent distributors in Europe in February 2004, and as of December 31, 2008, had established a European installed base of 409 systems in 217 hospitals, of which 380 had been sold and 29 were under evaluation. In other parts of the world as of December 31, 2008, we had an installed base of 49 systems, of which 45 had been sold and 4 were under evaluation.

In 2008, we had approximately 202 customers. We measure customers as those companies that have placed at least one order with us in the preceding twelve-month period. In 2008, 2007 and 2006 our largest customer, a European distributor, accounted for approximately 23%, 15% and 24%, respectively, of our net sales. The loss of our largest customer would have a material adverse effect on us. However, we believe that our relationship with our largest customer is good.

We typically provide the CoolGard and Thermogard systems to potential customers for an evaluation period, during which time we sell catheters to the hospitals for patient treatment however, during this time the customer is not required to purchase a minimum number of catheters. The majority of hospitals that have evaluated our products have purchased one or more systems and a supply of catheters.

We market our products worldwide to acute-care hospitals that have dedicated critical care units which provide advanced care for cardiac arrest, brain injury, cardiothoracic and trauma, burn and surgery patients. These are typically university and large community hospitals that have a level one or two trauma service designation and have a neuro-intensive care unit, medical intensive care unit, coronary care unit or emergency room. There are over 2,000 of these hospitals in the United States and a comparable number outside of the United States. Assuming a successful closing of the Asset Sale, we expect Zoll will continue to pursue clearances that we had been pursuing.

We have FDA clearance to market our products in the United States for fever control in certain neuro-intensive care patients and temperature management in cardiac and neuro surgery patients, and are exploring ways to obtain clearance for cardiac arrest. We have broader clearance to market our products in Europe, Canada and Australia, including clearance for cardiac arrest, and we are in the process of obtaining clearances to sell products in China, Japan and other Asian countries.

United States

We sell, market and distribute our products in the United States through a direct sales force supported by clinical application specialists. As of December 31, 2008, we employed 15 direct sales people, a director of sales, a vice president of worldwide sales and marketing, two regional sales managers, a corporate accounts manager, a government-military accounts manager, an international accounts manager, five clinical application specialists and a director of clinical education. Our clinical application specialists are trained nurse practitioners who assist with product service and installation, provide clinical education and promote catheter use among customers. Our sales strategy has been to target hospitals that are early adopters of new technologies and have large critical care units that may purchase multiple systems.

We are currently continuing to sell our products in the United States until the closing of the Asset Sale to Zoll. Zoll has its own sales force and we expect only a select number of our sales personnel will be hired by Zoll to sell our products after the Asset Sale. The balance of our sales force will cease employment with us after the Asset Sale.

International

We sell our products internationally through a network of independent distributors, each of which has exclusive rights to sell our products in a particular country or countries. As of December 31, 2008, we had a network of 33 distributors covering over 42 countries. We encourage our distributors to educate customers on the clinical efficacy, performance, ease of use, value and other advantages of our products. We provide our international distributors with clinical support, regional sales assistance and marketing materials. We have a European service center in the Netherlands to provide ongoing support to our customers and distributors. International sales accounted for 48%, 49% and 57% of total sales in 2008, 2007 and 2006, respectively.

Zoll has agreed to assume our international distributor agreements in connection with the Asset Sale, and we intend to transition these distributor arrangements to Zoll.

Competition

We principally compete with companies that sell conventional temperature management products such as cooling and warming blankets, ice packs and other external devices. We also compete with companies that sell newer surface temperature management products, such as Medivance, Inc., a privately held company that sells self-regulating cooling pads. Additionally, we compete with companies that have developed other intravascular approaches that are either pre-commercialization or in early stages of commercialization. These companies offer a smaller selection of catheters, which we believe have significantly less functionality than our catheters. In particular, we are the only temperature management company that sells catheters that can be inserted into the neck as well as the groin and that can function as a standard central venous catheter with multiple working ports. To compete effectively, we have to demonstrate that our products are attractive alternatives to other devices and treatments. We compete with other products on the basis of performance, safety, cost and ease of use. We believe our products compete favorably on the basis of these factors.

Despite what we believe are the benefits of our products, manufacturers of cooling and warming blankets may have more established products and customer relationships than we do, which could inhibit our market penetration efforts. We believe potential customers may feel they need to recoup the cost of products that they have already purchased from our competitors and therefore may choose not to purchase our products, or may delay such purchases. Some of our current and potential competitors may have significantly greater financial, research and development, manufacturing and sales and marketing resources than we have.

In addition, competitors that market what we believe to be less effective solutions, such as surface cooling and warming blankets and pads, often do so on the basis that such devices are less invasive than our catheters, which must be placed in a vein by a surgeon or other specialist. We strive to educate customers on the benefits of our superior effectiveness at regulating patient temperature, ease of patient access compared to surface devices, and the fact that a significant majority of patients eligible for our catheters would already be receiving a similar central venous catheter.

Intellectual Property and Proprietary Rights

We have invested considerable resources in our intellectual property strategy and rely on a combination of patents, copyrights, trademarks and trade secret laws, as well as confidentiality and invention assignment agreements, to protect our innovations. As of December 31, 2008, our products were covered by 34 issued U.S. patents. We also have U.S. patent applications pending directed to current and future products. As of December 31, 2008, our products were covered internationally by five issued patents. We have other foreign patent applications pending directed to current and future products. We intend to file for additional patents to strengthen our intellectual property rights. We believe our patent portfolio provides a competitive advantage in our key markets, particularly for inducing hypothermia with a catheter in specified indications and for fever control using a central venous catheter. Our patents covering these key markets generally expire between 2018 and 2022. Alsius, CoolGard, Cool Line, Thermogard, Icy, Fortius, Quattro and Solex are registered trademarks in the United States and the European Union. In connection with the Asset Sale, Zoll will acquire the right to our intellectual property portfolio.

We require our employees, consultants and certain vendors to sign confidentiality and invention assignment agreements. We cannot provide any assurance that employees and consultants will abide by the confidentiality or assignability terms of their agreements. Despite measures taken to protect our intellectual property, unauthorized parties may copy aspects of our products or obtain and use information that we regard as proprietary.

Zoll filed, but did not serve a patent infringement complaint against us in the United States District Court Central District of California on January 29, 2009, claiming that certain of our temperature management products infringe on two temperature management patents Zoll purchased from one of our defunct competitors. However, Zoll has agreed that during the pendency of our Asset Sale to Zoll, it will not serve us or take any action to pursue or resume the case. If the Asset Sale is not consummated, we would need to defend the action, which would be costly and have no guarantee of success.

Employees

As of December 31, 2008, we had approximately 103 employees. None of our employees are covered by collective bargaining agreements. We believe our future success will depend in large part upon our continued ability to attract, motivate, develop and retain highly skilled and dedicated employees. In conjunction with our announcement to sell our assets to Zoll, on February 20, 2009, we completed a reduction in force, whereby approximately 22 personnel were terminated. Approximately 71 personnel will remain through the closing of the Asset Sale to carry on our operations, which consist primarily of continuing U.S. sales and building additional products ordered by Zoll. It is our intent that all remaining personnel will cease their employment with us at the closing of the Asset Sale.

Available Information

We maintain an Internet website at www.alsius.com. Our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to such reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, along with our annual report to stockholders and other information related to our company, are available free of charge on this site as soon as reasonably practicable after we electronically file or furnish these reports with the SEC. Our Internet website and the information contained therein or connected thereto are not intended to be incorporated into this annual report on Form 10-K.

Item 1A.

Risk Factors

Our business, financial condition and results of operations can be impacted by a number of risk factors, any one of which could cause our actual results to vary materially from recent results or from our anticipated future results. Any of these risks could materially and adversely affect our business, financial condition and results of operations, which in turn could materially and adversely affect the price of our common stock or other securities.

Risks Related to Our Sale of Assets to Zoll

We have entered into an Asset Purchase Agreement with Zoll, whereby substantially all of our assets will be sold, and we will cease our operations. If we are not able to complete the Asset Sale, we expect that our limited financial resources will require that we immediately raise funds or cease operations.

Although we expect to complete the Asset Sale in the second quarter of 2009, it is possible that the Asset Sale will not be consummated for various reasons. Conditions to closing, which must be satisfied, include obtaining third party consents under certain contracts to transition them to Zoll, delivering certain minimum amounts of $3 million of finished inventory Zoll ordered from us at cost, and certain other conditions. If these conditions are not satisfied by June 30, 2009, Zoll may elect not to complete the Asset Sale. If these or other reasons cause the Asset Sale to not be completed, then we will not have sufficient financial resources to continue to operate independently, and we would need to immediately raise funds or cease operations and liquidate. Raising capital in the current market is extremely challenging, and if we are unable to do so, we expect that our cash resources would be insufficient to pay off our creditors, and that our stockholders would likely not receive any proceeds for their investment. If we were able to raise funds, the terms of such a financing would likely be extremely dilutive to the ownership of our existing investors

We will incur significant costs in connection with the Asset Sale which may decrease cash available for distribution to stockholders.

We currently expect to incur approximately $1.5 million of costs related to the Asset Sale. These expenses include, but are not limited to, financial advisory, legal and accounting fees and expenses, employee expenses, filing fees, printing expenses, and other related charges. We may also incur additional unanticipated expenses in connection with the Asset Sale. Approximately $0.65 million of the costs related to the Asset Sale, such as legal, financial advisory and accounting fees, will be incurred regardless of whether the Asset Sale is completed. These expenses are estimates and if they are greater than anticipated, that will decrease the remaining cash available for eventual distribution to stockholders in connection with our dissolution and liquidation.

We cannot be certain of the amount, if any, of the distribution to our stockholders under the Plan of Dissolution.

Liquidation and dissolution may not create value to our stockholders or result in any remaining capital for distribution to our stockholders. Our current estimate is that there will be $7.6 million in the aggregate, or $0.34 per share of our common stock, available for distribution over time to our stockholders. However, we cannot be certain of the precise amount available for distribution to our stockholders pursuant to the Plan of Dissolution. Claims, liabilities and expenses from operations (including, but not limited to, operating costs such as salaries, directors’ fees, directors’ and officers’ insurance, payroll and local taxes, legal and accounting fees and miscellaneous office expenses) will continue to be incurred as we seek to close the Asset Sale and wind down operations in dissolution. If claims, liabilities and expenses are greater than expected, that will reduce the amount available for distribution to our stockholders.

Distribution of assets, if any, to our stockholders could be delayed.

Subject to the consummation of the Asset Sale, we anticipate that an initial distribution of liquidation proceeds, if any, will be made to our stockholders within 90 days after the closing of the Asset Sale. As we liquidate our remaining assets and pay off our outstanding liabilities, including our headquarters lease, we will distribute additional liquidation proceeds, if any, to our stockholders as the Board deems appropriate. The negotiations regarding the termination of our headquarters lease may cause a delay to distribution of additional liquidation proceeds. Additionally, a creditor could seek an injunction against our making of distributions to our stockholders on the ground that the amounts to be distributed were needed to provide for the payment of our liabilities and expenses. Any action of this type could delay or substantially diminish the amount available for distribution to our stockholders.

Stockholders may be liable to our creditors for part or all of the amount received from us if reserves are inadequate.

We intend to establish a contingency reserve designed to satisfy any additional claims and obligations that may arise. Any contingency reserve may not be adequate to cover all of our claims and obligations. Under Delaware law, if we fail to create an adequate contingency reserve for payment of our claims and obligations during the three-year period after we file a certificate of dissolution with the Secretary of State of Delaware, each stockholder could be held liable for payment to our creditors of such stockholder’s pro rata share of amounts owed to creditors in excess of the contingency reserve. The liability of any stockholder would be limited to the amounts previously received from us by such stockholder in our dissolution. Accordingly, in such event, a stockholder could be required to return part or all of the distributions previously made to such stockholder, and a stockholder could receive nothing from us under our Plan of Dissolution. Moreover, if a stockholder has paid taxes on amounts previously received, a repayment of all or a portion of such amount could result in a situation in which a stockholder may incur a net tax cost if the repayment of the amount previously distributed may not cause a commensurate reduction in taxes payable in an amount equal to the amount of the taxes paid on amounts previously distributed.

Stockholders will not be able to buy or sell shares of our common stock after we dissolve.

We intend to discontinue trading of our stock on the Nasdaq Capital Market on, or as soon as possible after, the date on which we file our certificate of dissolution with the Secretary of State of the State of Delaware. This filing is expected to occur on or about 20 days after the mailing of our Information Statement to stockholders. After this time, there will be no further trading of our stock on the Nasdaq Capital Market or otherwise and we will not record any further transfers of our stock on our books except by will, intestate succession, or operation of law. Therefore, shares of our stock will likely not be freely transferable nor issuable upon exercise of outstanding options after the date of filing of a certificate of dissolution with the Secretary of State of the State of Delaware. All liquidating distributions from us after the date of filing of our certificate of dissolution with the Secretary of State of the State of Delaware will be made to our stockholders pro rata according to their respective holdings of stock as of the date of filing of the certificate of dissolution.

We intend to cease filing reports with the SEC.

We are currently obligated to comply with the applicable reporting requirements of the Exchange Act. In order to eliminate expenses we incur to comply with these requirements, and because our securities will no longer be traded, we intend to cease filing with the SEC, including annual and quarterly reports under the Exchange Act as soon as permissable under SEC rules after the filing of our certificate of dissolution with the Secretary of State of Delaware.

Risks Related to Our Business

We have not yet been able to finance our operations with the cash generated from our business. If the Asset Sale is not consummated and we do not generate cash sufficient to finance our operations, we will need additional financing to continue our growth.

We have not yet generated sufficient cash from operations to finance our business. Our financial statements have been prepared assuming that we would continue as a going concern. Operations to date have been financed principally through the private placement of equity securities, debt securities convertible to equity, and the cash we acquired in the Ithaka merger. We have not reported an operating profit for any year since our inception. From our inception through December 31, 2008, we had an accumulated deficit of $116.9 million, and at December 31, 2008 had cash and cash equivalents of $5.6 million to finance operations. We expect to incur net losses for the foreseeable future. These losses may be substantial and we may never achieve or maintain profitability. These factors raise substantial doubt about our ability to continue as a going concern, which is why we are completing the Asset Sale.

Our cash and cash equivalents on hand, and our projected cash flows, are not sufficient to take us to cash flow positive based on our current business plan. If we do not close the Asset Sale and were to try to continue operations, we will need additional debt or equity financing no later than the second quarter of 2009. Prior to agreeing to the Asset Sale, we were pursuing efforts to secure such funding but were not successful. The current market for debt and equity financing is challenging and the additional financing that we require may not be available at all or, if available, may be on terms unfavorable to us and our stockholders, and would substantially dilute current ownership interests.

Our loan with GE Capital had an outstanding balance of $3.7 million as of December 31, 2008, and requires that we make monthly principal payments of $266,667, until the loan is repaid in full in February 2010. Our agreements with GE Capital provide GE Capital with a lien on all of our principal assets other than intellectual property. If we default on a payment due to GE Capital, and the default is not waived, GE Capital can foreclose on our assets, including seizing our cash and investments accounts. If GE Capital were to seize our cash and investments accounts or otherwise foreclose on our assets, it would materially harm our business, and could force us to cease operations, declare bankruptcy, or both. We are currently in compliance with the covenants of our debt facility. However, if we do not close the Asset Sale and are unsuccessful in raising additional funds and we default on a payment to GE Capital, GE Capital could seize our remaining cash and investments. We cannot guarantee that we will be successful in raising additional funds.

Recent turmoil in the credit markets and the financial services industry may negatively impact our business, results of operations, financial condition or liquidity.

Recently, the credit markets and the financial services industry have been experiencing a period of unprecedented turmoil and upheaval characterized by the bankruptcy, failure, collapse or sale of various financial institutions and an unprecedented level of intervention from the United States federal government. These conditions make it extremely difficult for our customers, our vendors and us to accurately forecast and plan future business activities, and they could cause U.S. and foreign businesses to slow spending on our products and services, which would delay and lengthen sales cycles. Furthermore, during challenging economic times our customers may face issues gaining timely access to sufficient credit, which could result in an impairment of their ability to make timely payments to us. In addition, the recent economic crisis could also adversely impact our suppliers’ ability to provide us with materials and components, either of which may negatively impact our business, financial condition and results of operations.

Although we maintain allowances for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments and such losses have historically been within our expectations and the provisions established, we cannot guarantee that we will continue to experience the same loss rates that we have in the past, especially given the current turmoil of the worldwide economy. We cannot predict the timing, strength or duration of any economic slowdown or subsequent economic recovery. If the economy or markets in which we operate do not continue at their present levels, our business, financial condition and results of operations will likely be materially and adversely affected. Additionally, the combination of our lengthy sales cycle coupled with challenging macroeconomic conditions could have a combined negative impact on the results of our operations.

The long sales cycle for our systems may cause revenue and operating results to vary significantly quarter to quarter and year to year.

The decision to purchase our CoolGard and Thermogard systems and catheters often involves a significant commitment of resources and a lengthy evaluation process. We need to convince hospitals and critical care providers that our products are more effective than, and provide advantages over, competing temperature management products. Hospital purchases often involve a committee decision requiring approval of multiple decision makers including physicians, nurses and administrators. As a result, our sales process varies by hospital and country. In addition, a hospital typically uses funds from its capital equipment budget to purchase our CoolGard and Thermogard systems. Budget constraints and the need for multiple approvals within the hospital may delay the purchase decision for our products. This can result in a lengthy sales process, sometimes as long as six months to a year. The long sales cycle for our system may cause our revenue and operating results to vary significantly quarter to quarter and year to year. From time to time, we have experienced unit sales significantly lower than our prior forecasts, due primarily to longer sales cycles as customers evaluate a variety of alternative products to manage patient temperature, in addition to our products.

We depend on several large customers for our international sales, and a loss of or decline in sales to such customers may significantly reduce our revenue.

A significant portion of our sales in Europe are to a few key distributors. In 2006, Euromed and Fuchs Medical accounted for 24% and 4%, respectively, of our revenue. In 2007, Elan accounted for 15% of our revenue and Euromed and Fuchs Medical each accounted for 3%, respectively, of our revenue. In 2008, Elan accounted for 23% of our net revenues. From time to time, other international distributors may also account for a large portion of our revenue. Our contract with Euromed covered Austria and Germany. We decided to terminate our contract with Euromed effective May 2007, in order to enter into a new contract with Elan for Austria and Germany (which had previously acted as Euromed’s subdistributor of our products in Germany). Our contracts with Elan and other international distributors do not assure us significant minimum purchase volume. If a contract with a distributor is terminated for cause or by us for convenience, the distributor will have no obligation to purchase products from us. Our contracts with future distributors will typically have similar terms, and will not assure us of long-term minimum purchase volumes. The loss of, or any sudden decline in business from, any significant distributor, likely would lead to a significant decline in our revenue. We may not be able to retain this or other large customers or any other significant distributor. If we were to lose any large distributor, it may take significant time to replace the distributor and the revenue generated by them, and we may not ultimately be able to do so.

Our ability to market our CoolGard and Thermogard systems and accompanying disposable catheters in the United States is limited to fever control in neuro-intensive care patients and temperature management in cardiac and neuro surgery patients. If we want to expand our marketing claims to cardiac arrest or other uses, we will need to obtain additional FDA clearances or approvals, which may be expensive and time-consuming and may not be successful.

In the United States, the Food and Drug Administration, or FDA, has only cleared our CoolGard and Thermogard systems for use with our Cool Line catheter for fever reduction, as an adjunct to other antipyretic therapy, in intubated and sedated patients with cerebral infarction and intracerebral hemorrhage who require access to central venous circulation. Our CoolGard and Thermogard systems used with our Icy or Fortius catheter have been cleared in the United States only for use in cardiac surgery patients to achieve and maintain normothermia during surgery and in recovery and intensive care, and to induce, maintain and reverse mild hypothermia in neuro surgery patients in surgery and in recovery and intensive care. These clearances restrict our ability to market our products in the United States for treatment outside these specific cleared indications.

In 2004, we submitted a 510(k) notification to the FDA to have our products cleared for cardiac arrest. In March 2005, the FDA convened a meeting of the Circulatory System Devices Panel to consider the data submitted in the 510(k) notification. Following that meeting in 2005, we withdrew our request for cardiac arrest clearance because the FDA stated that it would require additional safety and efficacy data from a randomized, controlled human clinical trial. We decided not to conduct such a trial at that time because we wanted to focus on marketing our products for their cleared indications. Future trials may be expensive and time-consuming, and we cannot assure you that the FDA will ultimately grant our clearance or approval for such indications.

We may lose significant revenue and incur significant liability if it is determined under FDA regulations that we are promoting off-label use of our products.

If we do not obtain FDA clearance for cardiac arrest, or other indications, we may be at risk for liabilities and lost revenue as a result of off label use. A significant portion of our current revenue is, and anticipated future revenue increasingly will be, derived from the sale of our products to treat cardiac arrest. We have regulatory clearances to sell our products in Europe, Canada and in other countries outside the United States to treat cardiac arrest, but we do not have FDA clearance to sell our products in the United States to treat cardiac arrest. In the United States, the use of our products to treat cardiac arrest is and will be considered off-label use unless and until we receive regulatory clearance for use of our systems and catheters to treat cardiac arrest patients.

We do not track how physicians use our products after they are purchased, and cannot identify what percentage of our revenues is derived from off-label use. We are aware, however, that physicians in the United States are using our products off-label to treat cardiac arrest, and expect this use to increase. We believe this is due in large part to the 2006 American Heart Association recommendation that cooling be used to treat cardiac arrest. We have received increasing inquiries from U.S. physicians interested in using our products to treat cardiac arrest, in addition to cleared indications. In addition, in order to gather general market data and help us work with the FDA to design a clinical trial for cardiac arrest, in 2006 our field personnel began to ask hospitals why they are interested in purchasing our products. Of approximately 300 U.S. hospitals queried, over half indicated they are interested in cooling cardiac arrest patients, in addition to our cleared indications. We have also seen a similar level of interest in Europe, where our products are cleared for cardiac arrest. Based on these interest levels, we estimate it is possible that between 20% and 40% of our current U.S. revenues (or between 10% and 20% of our worldwide revenues) could be derived from off-label use. We also estimate that over time up to 50% of our U.S. revenues (or approximately 25% of our worldwide revenues) could be derived from purchases of our products to treat cardiac arrest.

Under the Federal Food, Drug and Cosmetic Act and other laws, we are prohibited from promoting our products for off-label uses. This means that we may not make claims about the safety or effectiveness of our systems and catheters for the treatment of cardiac arrest patients, and may not proactively discuss or provide information on the use of our products for the treatment of cardiac arrest patients, with very limited exceptions. Physicians, however, may lawfully choose to purchase our products and use them off-label. For example, we have clearance to sell our products to induce, maintain and reverse hypothermia in neurosurgery patients. A physician could use the same product to induce, maintain and reverse hypothermia in cardiac arrest patients, which would be an off-label use.

The FDA and other regulatory agencies actively enforce regulations prohibiting promotion of off-label uses and the promotion of products for off-label uses. A company that is found to have improperly promoted off-label uses may be subject to significant liability, including civil and administrative remedies, and even criminal sanctions. Due to these constraints, our sales and marketing efforts focus only on cleared indications for its products. When a hospital or physician expresses interest in potential off-label use, our field personnel (sales representatives and clinical specialists) have been trained to limit their discussion or training of our products only to their general attributes for cooling and warming of the patient, and the on-label indications. Our clinical applications specialists work in hospitals to instruct physicians and nurses on how to use our CoolGard and Thermogard systems, and how to run the system once our catheter has been inserted into the patient. The specialists do not, however, select which patients receive treatment or assist in the insertion of the catheter, both of which are done by the physician. The specialists thus do not determine the type of treatment (i.e., on-label or off-label) for which our products are used, and products are used in the same manner whether the patient is receiving an on- or off-label treatment. We do, upon request, disseminate information relating to the use of our products for off-label uses such as cardiac arrest. The FDA Modernization Act permits companies to respond in a non-promotional manner to unsolicited requests from doctors and hospitals for off label-information. We respond to such requests in a manner we believe is permitted under the FDA Modernization Act, by providing copies of and citations to articles that discuss off-label uses.

We do not believe any of our activities constitute promotion of off-label use. Should the FDA determine, however, that our activities constitute promotion of off-label use, the FDA could bring action to prevent us from distributing our products within the United States for the off-label use, could impose fines and penalties on us and our executives, and could prohibit us from participating in government healthcare programs such as Medicare and Medicaid. We could be required to substantially change our sales, promotion and educational activities. If we are prevented from distributing our products in the United States to treat cardiac arrest, we could lose an estimated 10% and 20% of our current revenues, and up to 25% based on future estimates. FDA actions concerning the promotion of off-label uses are typically expensive, disruptive and burdensome, and generate negative publicity. As a result, such an action could affect our reputation generally and interfere with our ability to sell our products even for approved uses. This would have an even greater negative impact on our sales and financial condition, and may require us to raise additional capital, which may not be available, or, if available may be dilutive to existing shareholders.

We face uncertainty related to pricing, reimbursement and health care reform, which could reduce our revenue. In addition, if we are found to be marketing our products for off-label uses, we can be barred from federal and state reimbursement programs, which could jeopardize all of our U.S. sales.

Sales of our products depend in part on the availability of coverage and reimbursement from third-party payors such as government insurance programs, including Medicare and Medicaid, private health insurers, health maintenance organizations and other health care related organizations. Both the federal and state governments in the United States, and foreign governments, continue to propose and pass new legislation affecting coverage and reimbursement policies, which are designed to contain or reduce the cost of health care. There may be future changes that result in reductions in current coverage and reimbursement levels for our products, and we cannot predict the scope of any future changes or the impact that those changes would have on our operations.

Adoption of our products by the medical community in the United States may be limited if doctors and hospitals do not receive full reimbursement for our products. Currently, existing procedure codes only cover reimbursement for a portion of the cost of our products. We do not have a specific Current Procedural Terminology, or CPT, reimbursement code for our products in the United States. The use of our product is paid for via two mechanisms. It is expensed within general Diagnosis Related Groups (DRG) and there is a small remuneration provided to the physician for a central line insertion. All our catheters have central line features. There are no disease specific billing codes that apply to the use of our product in the off label cardiac arrest indication. Physicians and hospitals have been using reimbursement codes related to central venous catheters or other critical care codes for our products, which provide only partial reimbursement.

Current cost control initiatives may decrease coverage and payment levels for existing and future products and, in turn, the price that we can charge for any existing product or those that we develop or market in the future. For example, the Medicare Modernization Act revised the Medicare payment methodology for many drugs covered under Medicare. We cannot predict the full impact of the new payment methodologies on our business. We are also impacted by efforts by private third-party payors to control costs. We are unable to predict all changes to the coverage or reimbursement methodologies that will be employed by private or government payors. Any denial of private or government payor coverage or inadequate reimbursement for procedures performed using our products could harm our business and reduce our revenue.

If we are found by the FDA or other federal or state authorities to be marketing our products for off-label uses, we may be temporarily or permanently barred from participating in government sponsored healthcare programs such as Medicare and Medicaid. We estimate that up to 25% of our current revenues may come from Medicare and Medicaid reimbursement to our customers. However, if we are barred from participating in such programs, hospitals may refuse to purchase our products altogether. As a result, such a ban from participating in these programs could jeopardize all of our U.S. sales.

The FDA has required that we place a warning label on our Cool Line catheter and that we collect safety data on the Cool Line. If the FDA concludes that the Cool Line catheters pose a statistically significant safety risk, it could require that we conduct additional clinical studies or recall the Cool Line in the United States, which could materially impact the sales and marketability of our Cool Line Products in the United States.

We obtained 510(k) clearances for the current indications for which we market our products. However, the FDA may seek to limit or revoke our clearances if safety or effectiveness problems develop. In 2002, we completed a 296-patient randomized, controlled clinical trial in support of our initial regulatory submission to the FDA. Based on the trial results, in August 2003, the FDA granted us 510(k) clearance for our CoolGard system and Cool Line catheter for treatment of fever reduction in patients with cerebral infarction and intracerebral hemorrhage. As a result of higher mortality rates in the clinical trial among patients treated for fever reduction following subarachnoid hemorrhage and primary traumatic brain injury, the FDA did not clear the Cool Line for these two indications. In addition, the FDA required that we place a warning label on our Cool Line catheter which states that the Cool Line is not cleared for treatment of these two indications, and discloses the mortality data associated with the two cleared and two non-cleared indications.

The FDA also required that we conduct a post market surveillance, or PMS, study of 200 patients treated with our Cool Line versus 200 patients from the same hospitals treated with conventional fever control therapies. Since the study began, we have submitted several quarterly and annual reports to the FDA on the progress of the PMS study. Currently, we have reported information regarding 208 patients enrolled in the study, which we believed showed good safety results. However, if these results or subsequent PMS safety data ultimately cause the FDA to conclude that our Cool Line catheters pose a statistically significant safety risk, the FDA could require that we conduct additional clinical studies or recall the Cool Line in the United States. Either of these potential FDA actions could materially impact the sales and marketability of our Cool Line products in the United States.

We have a limited history of commercial sales that makes it difficult to predict future performance and could impair our ability to grow revenue or achieve or maintain profitability.

We were incorporated in December 1991, and recapitalized and reorganized our operations and business in November 1998 to focus on intravascular temperature management. We began very limited sales of earlier versions of our products in Europe in December 2000 and began a more significant international sales launch of our current products in February 2004, when we started building a current network of independent distributors. We began sales in the United States in April 2004 through our own direct sales force. Consequently, we have a limited history of commercial sales of our products, which hinders us from accurately predicting sales and managing our inventory levels. Our inability to forecast future revenue or estimated life cycles of products may result in inventory-related charges that would negatively affect our gross margins and results of operations.

If we are unable to achieve continued market penetration with conventional temperature management products, we will be unable to compete effectively.

Our ability to compete effectively depends upon our ability to distinguish our products and includes such factors as:

●

product performance;

●

development of successful distribution channels, both domestically and internationally;

●

success and timing of new product development and introductions;

●

intellectual property protection; and

●

quality of customer support.

Cooling and warming blankets are more widely used and less expensive than our products. Newer surface cooling pads have been on the market for approximately the same amount of time as our products and are currently offered at prices similar to those offered for our products. If our potential customers have already purchased competing products, they may feel the need to recoup the cost of those products before they consider purchasing our products, even if they believe our products are superior. If we are unable to achieve continued market penetration, we will be unable to compete effectively. In addition, some of our current and potential competitors may have significantly greater financial, research and development, manufacturing and sales and marketing resources than we do. Our competitors could use their greater financial resources to acquire other companies to gain enhanced name and brand recognition and market share, as well as new technologies or products that could effectively compete with our products.

In addition, competitors that market surface cooling and warming blankets and pads often do so on the basis that such devices are less invasive than our catheters, which must be placed in a vein by a surgeon or other specialist. We strive to educate customers on the benefits of our superior effectiveness at regulating patient temperature, ease of patient access compared to surface devices, and the fact that a significant majority of patients eligible for our catheters would already be receiving a similar central venous catheter. However, in situations where a patient might not ordinarily receive a central venous catheter, or in situations where a standard catheter may be indicated but caregivers do not want to try our relatively newer catheter, we may not be able to compete effectively against less invasive temperature management products.

Our products are subject to product defects, recalls or failures, which could harm our financial results.

In manufacturing our products, we depend on third parties to supply various components. Many of these components require a significant degree of technical expertise to produce. Complex medical devices, such as our CoolGard and Thermogard systems, can experience performance problems in the field that require corrective action. If our suppliers fail to produce components to our specifications, or if the suppliers or we use defective materials or poor workmanship in the manufacturing process, the reliability and performance of our products will be compromised. We cannot assure you that our testing procedures will adequately identify all defects in our products or that component failures, manufacturing errors, or inadequate labeling, which could result in an unsafe condition or injury to the operator or the patient, will not occur. If any defects occur, we may incur warranty or repair costs, be subject to claims for damages related to product defects, be required to recall products, or experience manufacturing, shipping or other delays or interruptions as a result of these defects. Any recall would divert management attention and financial resources and could expose us to product liability or other claims, which may not be adequately covered by insurance, and may harm our reputation with customers. A recall involving our CoolGard or Thermogard systems could be particularly harmful to our business and financial results, because our CoolGard and Thermogard systems are necessary components that allow our catheters to work.

Our failure to maintain Nasdaq listing requirements could cause our common stock to be delisted.

We intend to delist and remove our stock from trading on the Nasdaq Capital Market immediately upon the closing of the Asset Sale. However, if the Asset Sale is not consummated and we elect to remain publicly traded, our stock could face the risk of being delisted.

If our common stock closes below $1.00 for thirty consecutive trading days, as occurred in the fourth quarter of 2008, we could be subject to Nasdaq delisting procedures if such noncompliance is not rectified within 180 calendar days, which would require our stock price to be $1.00 or more for at least 10 consecutive trading days. In the event we do not re-establish compliance within such 180 day period, we may be granted an additional 180 calendar days to re-establish compliance provided we at least satisfy the initial listing criteria of the Nasdaq Capital Market other than the minimum bid price requirement as of the expiration of the initial 180-day period.

Given the current extraordinary market conditions, NASDAQ suspended the bid price and market value of publicly held shares requirements through Monday April 20, 2009. On October 16, 2008 and as extended on December 18, 2008, NASDAQ filed an immediately effective rule change with the SEC, such that companies will not be cited for any new concerns related to bid price or market value of publicly held shares deficiencies. The duration of this relief is uncertain, however, and if minimum trading pricing are reinstated, and we do not meet them, we may be delisted from trading.

The loss of our Nasdaq listing would likely reduce trading activity in our common stock and make it more difficult for stockholders to sell their shares, and the threat of such a result could have a negative or dampening effect on our trading activity until such matter is resolved. Any decreased trading activity and added difficulty in trading our stock could have a negative impact on our stock price.

Risks Related to Our Operations

We are subject to risks associated with international sales that could harm our financial condition and results of operations.

International sales accounted for 48% and 49% of our revenue for 2008 and 2007, respectively. If we do not consummate the Asset Sale and are able to raise funds to continue operations, then we believe that a significant percentage of our future revenue will continue to come from international sales. In particular, we rely on a network of third-party distributors to market and sell our products in non-U.S. markets. The success of our international sales depends upon a number of factors beyond our control, including the effectiveness and skill of our distributors and their willingness to commit resources and prioritize the sale of our products. These parties may not have the same interests as we do in marketing our products. If these distributors do not actively sell our products, we may be unable to increase or maintain our current level of international revenue. In order to grow our business and expand the territories into which we sell our products internationally, we will need to attract additional skilled distributors in key geographic areas. We cannot assure you that distributors will be available on acceptable terms.

Additionally, international sales are subject to a number of other risks, including:

●

reduced protection for intellectual property rights in some countries;

●

export restrictions, trade regulations and foreign tax laws;

●

fluctuating foreign currency exchange rates;

●

foreign certification and regulatory requirements;

●

customs clearance and shipping delays; and

●

political and economic instability.

Additionally, our products and manufacturing facilities are subject to review and inspection by foreign regulatory agencies. Foreign authorities have become increasingly stringent and we and our distributors may be subject to more rigorous regulation in the future. Our failure or the failure of our distributors to comply with foreign regulations may restrict our and our distributors’ ability to sell our products internationally.

If we fail to maintain U.S. Food and Drug Administration and other government clearances for our current products and indications, or if we fail to obtain clearances for additional products and indications, our business would be significantly harmed.

Compliance with FDA, state and other regulations is complex, expensive and time-consuming. The FDA and state authorities have broad enforcement powers. Federal and state regulations, guidance, notices and other issuances specific to medical devices regulate, among other things:

●

product design, development, manufacturing and labeling;

●

product testing, including electrical testing, transportation testing and sterility testing;

●

pre-clinical laboratory and animal testing;

●

clinical trials in humans;

●

product safety, effectiveness and quality;

●

product manufacturing, storage and distribution;

●

pre-market clearance or approval;

●

record keeping and document retention procedures;

●

product advertising, sales and promotion;

●

PMS and medical device reporting, including reporting of deaths, serious injuries or other adverse events or device malfunctions; and

●

product corrective actions, removals and recalls.

Our failure to comply with any of the foregoing could result in enforcement actions by the FDA or state agencies, which may include fines, injunctions, penalties, recalls or seizures of our products, operating restrictions or shutdown of production. Any noncompliance may also result in denial of our future requests for 510(k) clearance or pre-market approval (PMA) of new products, new intended uses or modifications to existing products and could result in the withdrawal of previously granted 510(k) clearance or PMA. If any of these events were to occur, we could lose customers and our product sales, business, results of operations and financial condition would be harmed.

We may be unable to obtain or maintain international regulatory qualifications, clearances or approvals for our current or future products and indications, which could harm our international business.

Sales of our products outside the United States are subject to foreign regulatory requirements that vary widely from country to country. In addition, exports of medical devices from the United States are regulated by the FDA. We have obtained a Conformité Européenne, or CE Mark, in Europe for temperature management in patients for whom a central venous catheter is warranted. We have obtained a regulatory license to market our products in Canada for cooling and warming critical care patients, including for cardiac arrest. We have also obtained regulatory clearance to market our products in Australia for cooling and warming critical care patients, and have applied for similar clearances in China, Japan and other Asian countries. Complying with international regulatory requirements can be an expensive and time-consuming process and clearance or approval is not certain. The time needed to obtain clearance or approvals, if required by other countries, may be longer than that required for FDA clearance or approvals, and the requirements for such clearances may be more expensive. Foreign clearances may significantly differ from FDA requirements, and we may be unable to obtain or maintain regulatory qualifications, clearances or approvals in other countries. If we experience delays in receiving necessary qualifications, clearances or approvals to market our products outside the United States, or if we fail to receive those qualifications, clearances or approvals, we may be unable to market our products in international markets.

We may be subject to production halts and penalties if we or our third-party vendors fail to comply with FDA manufacturing regulations, which could harm our business.

We are required to comply with the FDA’s Quality System Regulation, or QSR, which applies to our facility and the facilities of our third-party component manufacturers and sterilizers. The QSR sets forth minimum standards for the design, production, quality assurance packaging, sterilization, storage and shipping of our products. Our products are also covered by FDA regulation that imposes record keeping, reporting, product testing and product labeling requirements. These requirements include affixing warning labels to our products, as well as incorporating certain safety features in the design of our products. The FDA enforces the QSR and performance standards through periodic unannounced inspections. We and our third-party component manufacturers, suppliers and sterilization providers are subject to FDA inspections at all times. Our failure or the failure of our component manufacturers, suppliers and sterilization providers to take satisfactory corrective action in response to an adverse QSR inspection or failure to comply with applicable performance standards could result in enforcement actions, including a public warning letter, a shutdown of manufacturing operations, a recall of products, and civil or criminal penalties.

Future enhancements of our products or new products we may develop may require new clearances or approvals or require that we cease selling such products until new clearances or approvals are obtained, which would harm our revenue and future profitability.

Modifications to our CoolGard and Thermogard systems may require that we apply for additional 510(k) clearances. Any modification to a 510(k)-cleared device that would constitute a change in its intended use, design or manufacture could require a new 510(k) clearance or, possibly, a PMA. If the FDA requires that we submit a new 510(k) or PMA application for the modifications, we may be required to cease promoting or to recall the modified product until we obtain clearance or approval. In addition, we could be subject to fines or other penalties. We may not be able to obtain additional 510(k) clearances or PMAs for new products or for modifications to, or additional indications for, our existing products in a timely fashion, or at all. Delays in obtaining future clearances would adversely affect our ability to introduce new or enhanced products in a timely manner, which in turn would harm our revenue and future profitability.

We will spend considerable time and money complying with federal, state and foreign regulations in addition to FDA regulations, and, if we are unable to fully comply with such regulations, we could face substantial penalties.

In addition to FDA regulations, we are subject to extensive U.S. federal and state regulations and the regulations of foreign countries in which we conduct business. The laws and regulations that affect our business, in addition to the Federal Food, Drug and Cosmetic Act and FDA regulations include, but are not limited to:

●

State consumer, food and drug laws, including laws regulating manufacturing;

●

the federal anti-kickback statute, which prohibits compensation for arranging a good or service paid for under federal health care programs;

●

Medicare regulations regarding reimbursement and laws prohibiting false reimbursement claims;

●

federal and state laws protecting the privacy of patient medical information, including the Health Insurance Portability and Accountability Act;

●

the Federal Trade Commission Act and similar laws regulating advertising and consumer protection; and

●

regulations similar to the foregoing outside the United States.

If our operations are found to be in violation of any health care laws or regulations, we may be subject to civil and criminal penalties, exclusion from Medicare, Medicaid and other government programs and curtailment of our operations. If we are required to obtain permits or licenses under these laws, we may be subject to additional regulation and incur significant expense. The risk of being found in violation of these laws is increased by the fact that many of them have not been fully or clearly interpreted by the regulatory authorities or the courts, and their provisions are subject to a variety of interpretations. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses, divert our management’s attention from the operation of our business and damage our reputation.

We depend upon a limited number of suppliers for the components of our products, making us vulnerable to supply shortages and price fluctuations, which could affect our customer demand and our revenue could decline.

Many of the components and materials used in our products are manufactured by a limited number of suppliers, and in some cases one supplier. Any supply interruption or an increase in demand beyond our suppliers’ capabilities could harm our ability to manufacture our products until a new source of supply is identified and qualified, which could result in lower revenue. Identifying and qualifying additional suppliers for the components used in our products, if required, may not be accomplished quickly or at all and could involve significant costs. If supply interruptions were to occur, our ability to meet customer demand would be impaired and customers may decide to cancel orders or switch to competitive products. Switching components or materials may require product redesign and new submissions to the FDA that could significantly delay production or, if the FDA refuses to approve the changes, stop us from manufacturing and selling our products.

We depend on key personnel to operate our business effectively, and the loss of key personnel could harm us.

Our success depends on the skills, experience, technical knowledge and efforts of our officers and other key employees. Alsius does not have employment contracts that require any of its officers or other key employees to remain with Alsius for any period. Any of our officers and other key employees may terminate their employment at any time. In addition, we do not maintain key person life insurance policies covering any of our employees. The loss of any of our senior management could disrupt our business.

If do not consummate the Asset Sale and were to remain a publicly traded company, then we will need to strengthen our internal controls over financial reporting in order to ensure that we are able to report financial results accurately and on a timely basis. If we fail to achieve and maintain effective controls and procedures for financial reporting, we could be unable to provide timely and accurate financial information.

Prior to our merger with Ithaka Acquisition Corp. in June 2007, we operated as a relatively small privately held company. We have incurred, and will continue to incur, substantial expenses related to improving our internal controls over financial reporting that we will need to strengthen so that we can meet our reporting obligations as a public company in a timely and accurate manner. However, we cannot assure you that material weaknesses, significant deficiencies and control deficiencies in our internal controls over financial reporting will not be identified when we are required to conclude on the effectiveness of our internal control over financial reporting. We will incur substantial expenses relating to improving our internal control over financial reporting. Our accounting and financial reporting functions may not currently have all of the necessary resources to ensure that we will not have significant deficiencies or material weaknesses in our system of internal control over financial reporting. The effectiveness of our internal control over financial reporting may in the future be limited by a variety of factors including:

●

faulty human judgment and simple errors, omissions or mistakes;

●

inappropriate management override of policies and procedures; and

●

the possibility that any enhancements to disclosure controls and procedures may still not be adequate to assure timely and accurate financial information.

If we fail to achieve and maintain effective controls and procedures for financial reporting, we could be unable to provide timely and accurate financial information. In accordance with Section 404 of the Sarbanes Oxley Act of 2002, we will be required to file an auditor’s attestation report on the effectiveness of our internal control over financial reporting when we file our annual report for our fiscal year ending on December 31, 2009.

If a natural or man-made disaster strikes our facility, we may be unable to manufacture products for a substantial amount of time and our revenue could decline.

We only have one manufacturing facility, which is located in Irvine, California. We are vulnerable to damage from natural disasters, such as earthquakes, fire, floods and similar events. If any disaster were to occur, our ability to operate our business could be seriously impaired. Our facility and the equipment that we use to produce our products could require substantial lead-time to repair or replace. In the event of a disaster, we would not have the ability to immediately shift production to another facility or rely on third-party manufacturers. If we were to shift production from one facility to another, we would need FDA authorization to manufacture the product in the new facility. This could take up to six months and we may not be able to outsource manufacturing during that time. We currently carry business interruption insurance with a policy limit of $5.2 million. Our insurance coverage may not be sufficient in scope or amount to cover potential losses, and we do not plan to purchase additional insurance to cover such losses due to the cost of such coverage. Any significant losses that are not recoverable under our insurance policies could seriously impair our business and financial condition.

Risks Related to Intellectual Property

Intellectual property rights may not provide adequate protection for our products, which could adversely affect our competitive position and may permit others to compete against us more effectively.

We rely on patent, copyright, trade secret and trademark laws and confidentiality agreements to protect our technology and products. As of December 31, 2008, our products were covered by 34 issued U.S. patents. We also have U.S. patent applications pending directed to current and future products. As of December 31, 2008, our products were covered internationally by five issued patents. We have other foreign patent applications pending directed to current and future products. Our patents covering our key markets generally expire between 2018 and 2022. Our foreign patents and applications include patents filed initially in certain countries and patents filed initially in the United States for which it then sought foreign coverage by way of the Patent Cooperation Treaty, or PCT. We cannot be certain which, if any, of its patents individually or as a group will permit us to gain or maintain a competitive advantage. Additionally, our patent applications may not issue as patents or, if issued, may not issue in a form that will provide meaningful protection against competitors or against competitive technologies. Furthermore, the issuance of a patent is not conclusive as to its validity or enforceability. Any patents we obtain may be challenged, invalidated or legally circumvented by third parties. Consequently, competitors could market products and use manufacturing processes that are substantially similar to, or superior to, ours. Competitors could reverse engineer our products and attempt to replicate them, design around our protected technologies or develop their own competitive technologies that fall outside of our intellectual property rights. In addition, the laws of many foreign countries will not protect our intellectual property rights to the same extent as the laws of the United States.

We use trademarks to protect our company name and certain of our product names. Alsius, CoolGard, Thermogard, Cool Line, Icy, Fortius, Quattro and Solex are registered trademarks in the United States and the European Union. We may also rely on common law protections from time-to-time for unregistered trademarks. Since no registration is required in order to establish common law rights to a trademark, it can be difficult to discover whether anyone has trademark rights in a particular mark. If we have to change our name or the name of our products due to infringement, we may experience a loss in goodwill associated with our brand name, customer confusion and a loss of sales.

We also seek to protect our intellectual property using confidentiality agreements with our employees, consultants and certain vendors. However, we may not be able to prevent the unauthorized disclosure or use of our technical knowledge or other trade secrets by consultants, vendors, former employees or current employees despite confidentiality agreements and other legal restrictions. Monitoring the unauthorized use and disclosure of our intellectual property is difficult, and we do not know whether the steps we have taken to protect its intellectual property will be effective.

Zoll filed, but did not serve, a patent infringement complaint against us claiming that certain of our temperature management products infringe upon two temperature management patents Zoll purchased from a defunct competitor of ours. Zoll has agreed that during the pendency of our Asset Sale to Zoll, it will not serve us or take any action to pursue or resume the case. However, if the Asset Sale were not to close and the litigation with Zoll were to resume, we would incur significant costs to defend it and pursue counterclaims against Zoll, and as litigation is unpredictable, there is no assurance as to whether we would achieve a favorable outcome. A loss may involve the payment of damages and/or an injunction prevent us from selling some or all of our products.

Our products could infringe the intellectual property rights of others. This may lead to costly litigation, result in payment of substantial damages or royalties and prevent us from using technology essential to our products.

In the medical device industry there is often extensive litigation and administrative proceedings regarding patent infringement and intellectual property rights. We cannot assure you that our products or methods do not infringe the patents or other intellectual property rights of others. Intellectual property litigation, with or without merit, is expensive and time-consuming and could divert management’s attention. If our products and their uses are successfully challenged, we could be required to pay substantial damages and be prohibited from using technologies essential to our products without the permission of their owners. We do not know whether permission to use others’ intellectual property would be available to us on satisfactory terms, or whether we could redesign our products to avoid infringement. We expect that any competitive advantage we may enjoy from our technologies, such as those of our CoolGard and Thermogard systems and catheters, may diminish over time as companies create their own innovations. We will only be able to protect our technologies from unauthorized use by others to the extent that we can pay to enforce our rights, including through litigation.

Item 1B.

Unresolved Staff Comments

None.

Item 2.

Properties

We do not own real property. Our principal executive office is located at 15770 Laguna Canyon Road, Suite 150, Irvine, California 92618, where we lease approximately 27,000 square feet under a lease that expires on December 31, 2011 with an option to extend the lease for an additional three-year term at market rates. We believe our existing facilities are adequate for our current needs. We also lease approximately 1,450 square feet in Wateringen, the Netherlands, for our European service center. This lease expires on May 31, 2010.

In connection with the Asset Sale, Zoll has agreed to assume the European service center lease. However, Zoll is not assuming our Irvine, California, headquarters lease. We intend to negotiate with our landlord to terminate our headquarters lease in connection with the Asset Sale, which may involve paying a termination fee. We estimate the total remaining charges under the term of the lease to be $1.4 million (including rent and related common area expenses) if were required to bear the entire lease cost.

Item 3.

Legal Proceedings

Zoll filed a patent infringement complaint against us in the United States District court Central District of California on January 29, 2009. However, Zoll agreed that during the pendency of our Asset Sale to Zoll, it will not serve the Company or take any action to pursue or resume the case. If the Asset Sale were not to close and the litigation with Zoll were to resume, we would incur significant costs to defend it and pursue counterclaims against Zoll. Our efforts to raise funding to support operations would have to include a substantial allocation to cover the cost of litigation. We believe we have a strong defense position and strong counterclaims to Zoll’s claims against us, but litigation is unpredictable and there is no assurance as to whether we would achieve a favorable outcome. A loss may involve the payment of damages and/or an injunction that prevents us from selling some or all of our products.

Item 4.

Submission of Matters to a Vote of Security Holders

No matters were submitted to a vote of our stockholders during the quarter ended December 31, 2008.

PART II

Item 5.

Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Our units, common stock and warrants are traded on the Nasdaq Capital Market under the symbols ALUSU, ALUS, and ALUSW, respectively. Prior to the close of our merger with Ithaka on June 21, 2007, the units, common stock and warrants traded on the OTCBB under the symbols ITHKU, ITHK and ITHKW, respectively. The following table sets forth the range of high and low closing bid prices for the units, common stock and warrants for the periods indicated. The over-the-counter market quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission and may not necessarily reflect actual transactions.

	Units				Common Stock				Warrants
	High		Low		High		Low		High		Low
Fiscal year ended December 31, 2008:
Fourth quarter	$	1.10	$	0.29	$	1.04	$	0.31	$	0.06	$	0.01
Third quarter		3.00		0.99		2.60		0.77		0.20		0.02
Second quarter		3.25		0.87		1.84		0.65		0.54		0.11
First quarter		5.25		3.25		4.08		1.80		0.85		0.26

Fiscal year ended December 31, 2007:
Fourth quarter	$	8.38	$	3.75	$	6.19	$	2.77	$	1.35	$	0.35
Third quarter		8.50		8.49		6.35		6.06		1.52		1.20
Second quarter		6.40		6.40		5.15		5.10		0.70		0.66
First quarter.		6.69		6.30		5.52		5.40		0.58		0.41

At February 27, 2009, there were approximately 35 holders of record of our common stock.

We have never paid cash dividends on our common stock. We currently intend to retain any earnings for use in our business, and do not anticipate paying cash dividends in the foreseeable future. In addition, under the terms of the Term Loan with Merrill Lynch Capital (now GE Capital), we are restricted from paying cash dividends on our common stock. We are restricted from making certain distributions, including cash dividends. We are currently in compliance with such restrictions.

Securities Authorized For Issuance Under Equity Compensation Plans

Set forth in the table below is information regarding outstanding equity awards made through equity compensation plans as of the end of the most recently completed fiscal year.

Equity Compensation Plan Information

Plan category	Number of securities to be issued upon exercise of outstanding options, warrants and rights	Weighted- average exercise price of outstanding options, warrants and rights	Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))
	(a)	(b)	(c)
Equity compensation plans approved by security holders

2006 Equity Incentive Plan	1,592,369	$2.86	1,887,521

Equity compensation plans not approved by security holders	N/A	N/A	N/A

Total	1,592,369	$2.86	1,887,521

For information regarding securities authorized for issuance under the Company’s equity compensation plans, see Part II, Item 8, Note 7 of this Report.

Item 6.

Selected Financial Data

The following table sets forth certain financial data regarding Alsius Corporation and should be read in conjunction with the consolidated financial statements and notes thereto (see Item 15, “Financial Statements” and Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations”). The income statement and balance sheet data presented below have been derived from Alsius Corporation’s consolidated financial statements. The merger between Alsius Medical and Ithaka in June 2007 was accounted for as a purchase in accordance with Statement of Financial Accounting Standards (“SFAS”) No. 141, “Business Combinations,” resulting in a new basis of accounting subsequent to the transaction. The newly merged company adopted the name Alsius Corporation and is the registrant today.

The merger with Ithaka, a publicly traded blank check acquisition company, was accounted for as a reverse acquisition. Under this method of accounting, Alsius Medical, the privately held operating company purchased by Ithaka, was the acquiring company for financial reporting purposes. In accordance with applicable guidance, the merger was considered to be a recapitalization. Accordingly, it was treated as the equivalent of Alsius Medical issuing stock for the net monetary assets of Ithaka accompanied by a recapitalization. The net monetary assets of Ithaka, primarily cash, were stated at their fair value, which was equivalent to the carrying value, and accordingly no goodwill or other intangible assets were recorded. The accumulated deficit of Alsius Medical was carried forward to the recapitalized company. The results below reflect those of Alsius Medical for the period before the merger closed on June 21, 2007. After June 21, 2007, the results reflect those of Ithaka and Alsius combined.

	Fiscal Year Ended
	2008 (3)			2007 (3)			2006			2005			2004
	(in thousands, except per share amounts)
Statement of Operations Data:
Revenue	$	12,461		$	9,114		$	5,979		$	3,223		$	1,641
Cost of revenue (1)		9,089			7,341			6,167			3,620			2,011
Gross margin (loss)		3,372			1,773			(188	)		(397	)		(370	)

Operating expenses:
Research and development (1)		4,234			3,920			2,948			3,466			3,331
Sales and marketing (1)		12,373			11,211			6,045			4,464			3,309
General and administrative (1)		4,992			5,471			4,352			1,491			1,348

Total operating expenses		21,599			20,602			13,345			9,421			7,988

Loss from operations		(18,227	)		(18,829	)		(13,533	)		(9,818	)		(8,358	)

Interest income		247			708			76			189			98
Interest expense		(660	)		(4,149	)		(2,064	)		(373	)		(5	)
Other income (expense)		—			35			(2,057	)		(120	)		45


Net loss	$	(18,640	)	$	(22,235	)	$	(17,578	)	$	(10,122	)	$	(8,220	)

Net loss per share – basic and diluted (2)	$	(0.89	)	$	(1.49	)	$	(1.60	)	$	(0.92	)	$	(0.75	)

Balance Sheet Data at Fiscal Year End:
Cash and cash equivalents	$	5,605		$	24,427		$	647		$	5,309		$	10,335
Working capital (deficit)		7,681			25,680			(8,763	)		5,294			11,784
Total assets		17,074			35,602			6,240			9,492			14,137
Long-term obligations		626			3,717			6,468			3,266			8
Redeemable convertible preferred stock		—			—			46,643			46,643			46,643
Shareholders’ equity (deficit)		9,368			24,012			(60,355	)		(43,358	)		(33,497	)

(1)

We adopted SFAS No. 123(R), “Share-Based Payment,” on January 1, 2006. As a result, stock-based compensation expense included within cost of revenue and operating expenses in fiscal 2008, 2007 and 2006 is based on the fair value of all stock options. Non-cash employee stock-based compensation expense included in our consolidated statements of operations was as follows (in thousands):

	Fiscal Year Ended
	2008		2007		2006		2005		2004
Cost of revenue	$	297	$	238	$	23	$	4	$	—
Research and development		587		582		48		30		—
Sales and marketing		1,176		985		149		110		—
General and administrative		1,489		1,582		354		116		—

(2)

For the periods prior to the close of our June 2007 merger with Ithaka, the net loss per share- basic and diluted is computed using 10,974 shares outstanding. The merger was, for financial reporting purposes, treated as a reverse acquisition and essentially a recapitalization. Because the number of shares outstanding following a reverse acquisition is significantly different from the number of shares outstanding prior to the combination, the weighted average shares outstanding for purposes of presenting net loss per share on a comparative basis has been retroactively restated to the earliest period presented in order to reflect the effect of the recapitalization that occurs in a reverse acquisition. In effect, the reverse acquisition is similar to a stock split for the accounting acquirer, and retroactively restating the weighted average shares outstanding is consistent with the accounting required by SFAS No. 128, “Earnings Per Share”, for stock splits, stock dividends, and reverse stock splits.

(3)	The results of Ithaka have been included in our financial statements since June 21, 2007.

Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis in conjunction with our Consolidated Financial Statements and related Notes thereto included in Part II, Item 8 of this Report and the Risk Factors included in Part I, Item 1A of this report, as well as other cautionary statements and risks described elsewhere in this report .

Overview

We are a medical device company that develops, manufactures and sells proprietary, innovative products to precisely control patient temperature in hospital critical care settings. Our products consist of our CoolGard and Thermogard temperature regulation systems, which are computer-controlled cooling and warming units, as well as five families of single-use catheters used exclusively with the systems—Cool Line, Icy, Fortius, Quattro and Solex. We market our products to acute care hospitals and critical care physicians through a direct sales force in the United States and independent distributors in international markets. Our revenue consists primarily of sales of the CoolGard system, single-use catheters and single use start-up kits which connect the catheter to the system. In the first quarter of 2007, we introduced our new Thermogard system, a computer controlled cooling and warming unit used with our catheters that is similar to the CoolGard, but which contains additional features for use in surgical applications. In June 2007, we introduced our “Hospital Monitoring Interface Accessory” (HMIA). The HMIA enables the caregiver to display the patient’s temperature on both the Alsius system and the patient monitor. The HMIA is compatible with the majority of patient monitoring systems. In the first quarter of 2008, we introduced the Thermogard XP system, which is similar to the Thermogard, but with additional power and features.

We began selling our products in the United States in April 2004 and, as of December 31, 2008, had established a U.S. installed base of over 327 systems in 169 hospitals, of which 293 had been sold and 34 were under evaluation. Our U.S. installed base includes 10 systems that we sold in the second quarter of 2008 to a third party who intends to rent them to hospitals. We began building a current network of independent distributors in Europe in February 2004, and as of December 31, 2008, had established a European installed base of over 409 systems in 217 hospitals, of which 380 had been sold and 29 were under evaluation. In other parts of the world as of December 31, 2008, we had an installed base of 49 systems, of which 45 had been sold and 4 were under evaluation. We generated revenues of $12.5 million in the year ended December 31, 2008, which represents revenue growth of 37% from the year ended December 31, 2007. We had a net loss of $18.6 million in the year ended December 31, 2008. International sales accounted for 48% of our revenue in the year ended December 31, 2008.

We have FDA clearance to market our products in the United States for fever control in certain neuro-intensive care patients and temperature management in cardiac and neuro surgery patients. We have broader clearance to market our products in Europe, Canada, China and Australia, including clearance for cardiac arrest, and are in the process of obtaining clearances to sell our products in Japan and other Asian countries. We only market our products for treatments in the specific cleared indications; however, this does not prevent physicians from using our products for non-cleared, or off-label, uses. As of December 31, 2008, we employed 15 direct sales people, a director of sales, a vice president of worldwide sales and marketing, two regional sales managers, a corporate accounts manager, a government-military accounts manager, an international accounts manager, five clinical application specialists and a director of clinical education in the United States and over 33 independent international distributors covering over 42 countries.

On February 19, 2009, we entered into a Purchase Agreement to sell substantially all of our assets to Zoll, as discussed elsewhere herein. We expect to complete the Asset Sale in the second quarter of 2009. However, if the Asset Sale is not consummated, our cash position would require that we immediately raise working capital or cease operations.

Results of Operations

Years Ended December 31, 2008 and 2007

Revenue. Revenue was $12.5 million for the year ended December 31, 2008, an increase of $3.4 million or 37%, from $9.1 million for the year ended December 31, 2007. During 2008, we introduced a new product, Thermogard XP, resulting in an approximate 20% increase in average selling prices for systems. Our revenue also reflects an approximate 12% increase in average selling prices for disposable units. During the year ended December 31, 2008, we sold 10,392 catheters and 9,668 start-up kits, an increase of 40% and 43%, respectively, from the 7,436 catheters and 6,750 start-up kits sold during the year ended December 31, 2007. Sales of our CoolGard and Thermogard systems decreased from 218 in 2007 to 211 during 2008. Our 2007 results include the sale of 23 systems in one European country, France, which has not recurred in 2008. The sales in 2007 were purchased by our French distributor to provide systems for two multiple-site clinical trials. These systems were used for the trials and subsequently sold to the hospitals in 2008. Sales of our CoolGard and Thermogard systems accounted for 41% and 48% of revenue and sales of catheters and start-up kits accounted for 53% and 47% of our revenue for the year ended December 31, 2008 and 2007, respectively. Sales in the United States accounted for 52% of our revenue for 2008, compared to 49% for 2007.

Cost of revenue. Cost of revenue consists of costs of materials, products purchased from third-parties, manufacturing personnel, freight, depreciation of property and equipment, royalties paid to technology licensors, manufacturing overhead, warranty expenses and inventory reserves. Royalties paid to third parties include two worldwide licenses related to our catheters. One license covers a coating used on our catheters and requires that we pay a royalty of between 2.0% and 3.5% on net revenue generated by all catheters. The other license covers technology used in our Cool Line catheter and requires that we pay a royalty of 2.5% on net revenue generated by the Cool Line catheter.

Cost of revenue was $9.1 million for the year ended December 31, 2008, an increase of $1.8 million or 25%, from $7.3 million for the year ended December 31, 2007. Cost of revenue increased primarily due to increased sales volume. These costs include approximately $0.4 million related to a write-down of and a reserve on our physical inventory in the quarter ended September 30, 2008. As a percentage of revenue, cost of revenue decreased from 81% of sales for 2007, to 73% of sales for 2008. The percentage decrease was primarily due to the realization of cost reduction programs and higher average selling prices as a result of an increase in sales to domestic U.S. customers, to whom we sell directly, versus international sales which are made through distributors. Stock based compensation increased in the year ended December 31, 2008 by $0.1 million as compared to the year ended December 31, 2007 due to the grant of stock options and restricted stock units under our 2006 Equity Incentive Plan.

Research and development expense. Research and development expense consists of costs related to our regulatory and product development activities. Research and development expense has been, and we anticipate in the future will be, highest when we are actively engaged in human clinical trials to support new regulatory clearances. Research and development expense was $4.2 million for the year ended December 31, 2008, an increase of $0.3 million, or 8%, from $3.9 million for the year ended December 31, 2007. This increase is primarily attributable to compensation related costs of $0.1 million associated with increased headcount, $0.3 million associated with material cost to test two new catheters, partially offset by $0.1 million in reduced regulatory costs to clear products for sale in Japan.

Sales and marketing expense. Sales and marketing expense consists of costs related to our direct sales force personnel, clinical application specialists, travel, trade shows, advertising, entertainment, and marketing materials provided to our international distributors. Sales and marketing expense was $12.4 million for the year ended December 31, 2008, an increase of $1.2 million, or 11%, from $11.2 million for the year ended December 31, 2007. This increase was primarily attributable to the growth of our direct sales force and marketing activities to support our worldwide market expansion, resulting in increased compensation and commission costs of $0.8 million, and increased advertising, public relations and outside services expenses of $0.3 million. Stock based compensation increased by $0.2 million associated with our 2006 Equity Incentive Plan.

Interest income. Interest income was $0.2 million for the year ended December 31, 2008, a decrease of $0.5 million, or 71%, from $0.7 million for the year ended December 31, 2007. This decrease was due to the lower levels of cash invested.

Interest expense. Interest expense was $0.7 million for the year ended December 31, 2008, a decrease of $3.4 million, or 83%, from $4.1 million for the year ended December 31, 2007. Interest expense in 2008 primarily resulted from our borrowings from Merrill Lynch Capital (now GE Capital). In 2007, we incurred $0.2 million of interest on these borrowings, $0.2 million related to borrowings from other finance companies, and $2.6 million related to the bridge notes, all of which were repaid in the Ithaka merger in June 2007.

Other income (expense). Other income (expense) was zero for the year ended December 31, 2008 as compared to $0.04 million of other expense for the year ended December 31, 2007. This was primarily due to the decrease in the fair value adjustments of the warrant liabilities and embedded derivatives associated with the May 2005 secured promissory note and the 2006 bridge notes as these items were either repaid or converted in the Ithaka merger in June 2007.

Years Ended December 31, 2007 and 2006

Revenue. Revenue was $9.1 million for the year ended December 31, 2007, an increase of $3.1 million or 52%, from $6.0 million for the year ended December 31, 2006. The increase was attributable to an increase in the sale of our catheters and start-up kits due to our growing installed base of CoolGard and Thermogard systems. During 2007, we sold 7,436 catheters and 6,750 start-up kits, an increase of 32% and 42%, respectively, from the 5,613 catheters and 4,754 start-up kits sold during 2006. In addition, we increased sales of our CoolGard and Thermogard systems from 157 in 2006 to 218 in 2007. Sales of our CoolGard and Thermogard systems accounted for 48% and 48% of revenue and sales of catheters and start-up kits accounted for 47% and 48% of our revenue for 2007 and 2006, respectively. Sales in the United States accounted for 51% of our revenue for 2007 and 43% for 2006. The increase in sales to domestic customers, to whom we sell directly, allowed us to realize higher average selling prices.

Cost of revenue was $7.3 million for the year ended December 31, 2007, an increase of $1.1 million or 18%, from $6.2 million for the year ended December 31, 2006. Cost of revenue increased primarily due to increased sales volume. As a percentage of revenue, cost of revenue decreased from 103% of sales in 2006 to 81% of sales in 2007. The percentage decrease was primarily due to higher average selling prices as a result of an increase in sales to domestic U.S. customers, to whom we sell directly, versus international sales which are made through distributors. The decrease in cost of revenue was partially offset by increased production costs due to labor and materials costs of $0.2 million in 2007 to replace catheter components that did not meet quality specifications and $0.5 million increase in compensation and benefits related to the higher headcount needed to support increased production. Stock based compensation also increased $0.2 million associated with our new 2006 equity incentive plan.

Research and development expense. Research and development expense consists of costs related to our regulatory and product development activities. Research and development expense has been, and we anticipate in the future will be, highest when it is actively engaged in human clinical trials to support new regulatory clearances. Research and development expense was $3.9 million for the year ended December 31, 2007, an increase of $1.0 million, or 34%, from $2.9 million for the year ended December 31, 2006. The increase was primarily due $0.2 million in clinical research costs, specifically for testing and qualification process in Japan, and increased compensation and benefits of $0.3 million related to the higher headcount needed to support the activities. Stock based compensation also increased $0.5 million associated with our new 2006 equity incentive plan.

Sales and marketing expense. Sales and marketing expense consists of costs related to our direct sales force personnel, clinical application specialists, travel, trade shows, advertising, entertainment, and marketing materials provided to our international distributors. Sales and marketing expense was $11.2 million for the year ended December 31, 2007, an increase of $5.2 million, or 87%, from $6.0 million for the year ended December 31, 2006. This increase was primarily attributable to the growth of our direct sales force and marketing activities to support our worldwide market expansion resulting in increased compensation costs of $1.7 million, increased travel costs of $0.9 million, increased advertising and promotion expenses of $0.6 million, increased trade show and meeting expenses of $0.4 million, increased public relations expense of $0.1 million, increased commissions of $0.3 million corresponding to increase in sales, and increased outside services expenses of $0.2 million. Stock based compensation also increased by $0.8 million associated with our new 2006 equity incentive plan.

General and administrative expense. General and administrative expense consists of costs related to personnel, legal, accounting and other general operating expenses. General and administrative expense was $5.5 million for the year ended December 31, 2007, an increase of $1.1 million or 25%, from $4.4 million for the year ended December 31, 2006. The increase was primarily attributable to an increase in stock based compensation of $1.2 million, initial NASDAQ filing fees of $0.1 million, increased board of directors compensation and higher insurance costs of $0.2 million, and $0.1 million increase in consulting related to our Sarbanes-Oxley compliance efforts. These increases are partially offset by decreased professional fees (legal, accounting and printing) of $0.5 million as we undertook significant efforts in early 2006 related to an initial public offering (IPO) prior to commencing the merger transaction with Ithaka in late 2006. The IPO costs were expensed when we withdrew our offering.

Interest income. Interest income was $0.7 million for the year ended December 31, 2007, an increase of $0.6 million, or 600%, from $0.1 million for the year ended December 31, 2006. This increase was due to the investing the cash and cash equivalents we obtained in the merger.

Interest expense. Interest expense was $4.0 million for the year ended December 31, 2007, an increase of $1.9 million, or 90%, from $2.1 million for the year ended December 31, 2006. The increase in interest expense resulted from an additional $1.1 million incurred on our convertible bridge notes issued from April 2006 through February 2007, $1.1 million incurred on promissory notes issued in February and May 2007 in connection with our loan from Merrill Lynch Capital, and $0.1 million incurred on our borrowings from Cheyne Capital, partially offset by a decrease in interest expense of $0.3 million related to our borrowings from Oxford Finance which we repaid in February 2007. The interest expense on the bridge notes included a discount associated with the warrants issued with the bridge notes.

Other expense. Other expense was $0.1 million for the year ended December 31, 2007, a decrease of $2.0 million, or 95%, from the $2.1 million for the year ended December 31, 2006. The decrease is due to the changes in fair value of the warrant and embedded derivative liabilities associated with our debt instruments. The underlying debt instruments were converted or repaid in 2007.

Quarterly Financial Information (Unaudited)

The following is a summary of the Company’s unaudited quarterly results of operations for fiscal 2008 and 2007 (in thousands, except share and per share data).

	Fiscal Quarter Ended
Fiscal 2008	December 31			September 30			June 30			March 31

Revenues	$	3,840		$	3,096		$	3,022		$	2,503
Gross margin		1,301			522			957			592
Net loss		(3,547	)		(4,862	)		(4,734	)		(5,497	)
Net loss per share, basic and diluted		(0.17	)		(0.23	)		(0.22	)		(0.27	)

	Fiscal Quarter Ended
Fiscal 2007	December 31			September 30			June 30			March 31

Revenues	$	2,709		$	1,880		$	2,500		$	2,025
Gross margin		754			608			331			80
Net loss		(5,665	)		(5,252	)		(4,959	)		(6,359	)
Net loss per share, basic and diluted (1)		(0.31	)		(0.29	)		(0.42	)		(0.58	)

(1)

For the periods prior to the close of the June 2007 merger with Ithaka, the net loss per share- basic and diluted is computed using 10,974,100 shares outstanding. The merger was, for financial reporting purposes, treated as a reverse acquisition. Because the number of shares outstanding following a reverse acquisition is significantly different from the number of shares outstanding prior to the combination, the weighted average shares outstanding for purposes of presenting net loss per share on a comparative basis has been retroactively restated to the earliest period presented in order to reflect the effect of the recapitalization that occurs in a reverse acquisition. In effect, the reverse acquisition is similar to a stock split for the accounting acquirer, and retroactively restating the weighted average shares outstanding is consistent with the accounting required by SFAS No. 128, “Earnings Per Share”, for stock splits, stock dividends, and reverse stock splits.

Liquidity and Capital Resources (dollars in thousands, except share and per share data)

From our inception, and prior to the merger with Ithaka in June 2007, we financed our operations primarily through private sales of preferred stock, with aggregate net proceeds of $76.5 million in cash. From April 2006 through February 2007, we borrowed an aggregate amount of $10.6 million from existing shareholders (the 2006 bridge notes). We issued to each lending party unsecured convertible promissory notes bearing interest at 8% per annum. In February 2007, we borrowed $8.0 million from Merrill Lynch Capital (subsequently acquired by GE Capital) of which $3.0 million was used to pay existing debt. We issued a secured promissory note to Merrill Lynch Capital bearing interest at 6.5% over the LIBOR rate with interest only payments for the first six months and interest and principal payments for 30 months thereafter. In connection with this term loan, we issued a warrant having a contractual life of ten years. We estimated the fair value of the warrant using the Black-Scholes option pricing model. The estimated fair value of $0.2 million resulted in a discount to the term loan. The discount will be amortized to interest expense using the effective interest method over the life of the term loan.

In May 2007, we and Merrill Lynch Capital amended our promissory note to provide for an additional $2.0 million of borrowing for an aggregate total of $10.0 million. The second tranche of $2.0 million was funded on May 11, 2007 with interest at the same rate as the original note and it was repaid upon the close of the Ithaka merger in June 2007. In connection with the second tranche, we did not issue any additional warrants but we did incur a fee of $0.2 million, which was paid out of proceeds. In June 2007, we borrowed $1.5 million in an unsecured promissory note from a financing company, Cheyne Capital, a shareholder of Ithaka. The interest rate on this note was 15% and we incurred a fee of 7.5% which was paid out of proceeds. We repaid this unsecured promissory note in July 2007. We consummated our merger with Ithaka in June 2007, and in that transaction we acquired approximately $40.0 million of net assets (see Note 3 of the accompanying Notes to Consolidated Financial Statements).

As of March 31, 2009, we owed a total of $2.9 million to GE Capital. In connection with the closing of the Asset Sale to Zoll, we intend to repay GE Capital in full in the amount of $3.1 million which consists of principal and estimated accrued interest and fees through the closing.

We have incurred significant net losses since inception and have relied on our ability to obtain financing. As of December 31, 2008, we had $5.6 million in cash and cash equivalents to finance operations and satisfy our obligations. If the Asset Sale is consummated, we will have sufficient capital to meet our reduced operational needs for the next twelve months. If the Asset Sale is terminated, unless we are able to secure debt or equity financing, we will not have sufficient capital to meet our operational needs for the next twelve months.

We have incurred significant net losses since inception, and have relied on our ability to obtain financing, which to date has been through a merger, the sale of redeemable convertible preferred stock and the issuance of promissory notes. We expect operating losses and negative cash flows to continue for the foreseeable future as we incur additional costs and expenses related to continued development of our products, and obtaining FDA approval for new indications. These factors raise substantial doubt about our ability to continue as a going concern. The accompanying financial statements have been prepared on a going concern basis that contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The financial statements do not include adjustments relating to the recoverability of recorded asset amounts or the amounts or classification of liabilities that might be necessary should we be unable to continue as a going concern. Our ability to meet our obligations in the ordinary course of business is dependent upon our ability to establish profitable operations, or to secure other sources of financing to fund operations.

Years Ended December 31, 2008 and 2007

As of December 31, 2008, we had cash and cash equivalents of $5.6 million, working capital of $7.7 million and an accumulated deficit of $116.9 million.

Cash flows used in operating activities. Net cash used in operations was $15.1 million for the year ended December 31, 2008 and $20.7 million for the year ended December 31, 2007. The net cash used in each of these periods primarily reflects the net loss for those periods, offset by non-cash charges such as depreciation and amortization, stock-based compensation, amortization of debt discounts and the change in fair value of warrant liabilities associated with the May 2005 and February 2007 secured promissory notes and Merrill Lynch Capital Term Loan and the change in the fair value of the warrant liabilities and embedded derivatives associated with our 2006 bridge notes. Non-cash charges for depreciation and amortization, stock-based compensation, amortization of debt discounts and debt issuance costs and the change in fair value of warrant liabilities and embedded derivatives totaled $4.3 million and $6.6 million for the years ended December 31, 2008 and 2007, respectively, representing a $2.3 million decrease. This decrease was primarily comprised of a $0.2 million increase in stock-based compensation offset by a decrease of $2.6 million of amortization of discounts on promissory notes since we converted or repaid our debt instruments in June 2007.

Cash flows used in investing activities. Net cash used by investing activities was $1.0 million for the year ended December 31, 2008 and consisted of capital expenditures. Net cash provided by investing activities was $40.6 million for the year ended December 31, 2007 and consisted $41.5 million of net cash received in the Ithaka merger and offset by $0.9 million of capital expenditures. The increase in capital expenditures is primarily attributable to the January 2008 release of our Thermogard XP system and the subsequent placement of these systems into our evaluation equipment pool.

Cash flows from financing activities. Net cash flows used by financing activities were $2.7 million for the year ended December 31, 2008 compared to $3.9 million provided by financing activities for the year ended December 31, 2007. Cash flows from financing activities in 2008 reflects $0.5 million in net proceeds from our warrant exchange program offset by $3.2 million in repayment of the borrowings from Merrill Lynch.

Cash flows provided by financing activities in the year ended December 31, 2007 were $3.9 million and primarily represent $13.0 million in proceeds from the 2006 bridge notes and other borrowings, offset by $7.7 million in principal payments, $0.9 million in payments to convert common stock in connection with the Ithaka acquisition, and $0.3 million of debt issuance costs.

Years Ended December 31, 2007 and 2006

As of December 31, 2007, we had cash and cash equivalents of $24.4 million, working capital of $25.7 million and an accumulated deficit of $98.2 million.

Cash flows used in operating activities. Net cash used in operations was $20.7 million for the year ended December 31, 2007 and $11.9 million for the year ended December 31, 2006. The net cash used in each of these periods primarily reflects the net loss for those periods, offset by non-cash charges such as depreciation and amortization, stock-based compensation, amortization of debt discounts and the change in fair value of warrant liabilities associated with the May 2005 and February 2007 secured promissory notes and Merrill Lynch Capital Term Loan and the change in the fair value of the warrant liabilities and embedded derivatives associated with our 2006 bridge notes. Non-cash charges for depreciation and amortization, stock-based compensation, amortization of debt discounts and the change in fair value of warrant liabilities and embedded derivatives totaled $6.5 million and $4.3 million for the years ended December 31, 2007 and 2006, respectively, representing a $2.2 million increase. This increase was comprised of a $1.4 million increase in discount amortization associated with the 2006 bridge notes, and increase in stock-based compensation of $2.8 million during 2007, offset by a decrease of $2.1 million of change in fair value of warrant liabilities associated with our debt instruments since we converted or repaid our debt instruments in 2007.

For the year ended December 31, 2007, operating assets and liabilities aggregated to a net decrease of cash of $5.0 million, representing an increased level of all operating assets and liabilities, primarily related to building inventories by $4.3 million to support our increased sales growth.

Cash flows used in investing activities. Net cash provided by investing activities was $40.6 million for the year ended December 31, 2007 and consisted of $41.5 million in net cash received in the merger with Ithaka, offset by $0.9 million in capital expenditures. Net cash used in investing activities was $0.3 million for the year ended December 31, 2006, and consisted of capital expenditures.

Cash flows from financing activities. Cash flows from financing activities were $3.9 million for the year ended December 31, 2007 and $7.5 million for the year ended December 31, 2006. Cash flows from financing activities in 2007 reflected $1.5 million in proceeds from the 2006 Bridge Notes, $10.0 million in proceeds from the promissory notes issued in February and May 2007 to Merrill Lynch Capital, and $1.5 million in proceeds on the unsecured Cheyne Capital promissory note, offset by $3.1 million for the payment in full of the 2005 promissory note with Oxford Finance Corporation, $3.1 million in repayment of the borrowings from Merrill Lynch and $1.5 million in full repayment of our borrowings from Cheyne Capital. We also paid $0.3 million in debt issuance costs on these borrowings. In 2007 we also spent $0.9 million to repurchase common stock warrants we acquired in the merger.

Cash flows from financing activities in the year ended December 31, 2006 were $7.5 million and represents $9.1 million in proceeds from the 2006 Bridge Notes, offset by $1.5 million in principal payments on the 2005 promissory note.

Uses of Capital Resources

The following table summarizes information about our material contractual obligations as of December 31, 2008:

Contractual Obligations	Total		Less Than 1 Year		1-3 Years		3-5 Years		More Than 5 Years
	(in thousands)
Operating leases	$	1,126	$	378	$	748	$	—	$	—
Long-term debt (excluding discount of $51)	$	3,773	$	3,216	$	557	$	—	$	—
Capital leases	$	82	$	27	$	55	$	—	$	—

Operating leases. We lease our facility under a noncancelable operating lease which, as amended in August 2008, expires in December 2011 with an option to extend the lease for an additional three-year term at market rates. Under the lease, we are required to pay for insurance, taxes, utilities and building maintenance, commonly known as a “triple net” lease. We also lease a small space for our European service center in Wateringen, the Netherlands, under a lease that expires on May 31, 2010. In November 2007, we entered into a new operating lease commitment for an automobile, under a lease that expires in November 2011.

In connection with the Asset Sale, Zoll has agreed to assume the European service center lease. However, Zoll is not assuming our Irvine, California, headquarters lease. We are currently negotiating with our landlord to terminate our headquarters lease in connection with the Asset Sale, which may involve paying a one-time termination fee. We estimate the total remaining charges under the term of the lease to be $1.4 million (including rent and related common area expenses) if we are required to bear the entire lease cost.

Long-term debt . The senior secured credit facility with Merrill Lynch Capital (now GE Capital), entered into in February 2007 and amended in May 2007, consists of a $10.0 million term loan with an interest rate of one month LIBOR plus 6.50%, and the outstanding balance at December 31, 2008 is $3.7 million. The term loan requires interest only payments for the first six months and interest and principal payments for each month thereafter through February 2010. Based on the current interest rate at December 31, 2008, we estimate that our interest payments for fiscal 2009 will be $206 and in fiscal 2010 until maturity will be $6. As of March 31, 2009, we owed a total of $2.9 million to GE Capital. In April 2008, we entered into a new equipment financing agreement for $51 which requires monthly payments through April 2011.

Capital leases. In June 2006, we entered into a lease commitment for computer equipment over a period of 63 months for a total value of $106. In November 2006, we entered into a lease commitment for office equipment over a period of 60 months for a total value of $14. In April 2007, we entered into a lease commitment for machinery and equipment over a period of 48 months for a total value of $14.

Uncertain tax liabilities. At December 31, 2008, we had uncertain tax positions which ultimately could result in a tax payment.

Plan of Dissolution (dollars in thousands, except share and per share data)

After the consummation of the Asset Sale, we anticipate that an initial distribution of liquidation proceeds will be made to our stockholders within 90 days. As we liquidate our remaining assets and pay off our outstanding liabilities, we will distribute additional liquidation proceeds, if any, to our stockholders as the Board or its authorized designees deem appropriate. A final $1 million will be held in trust for one year from the closing date of the Asset Sale to cover potential indemnity obligations to Zoll under the Purchase Agreement for the Asset Sale. We currently estimate that the aggregate amount ultimately distributed to our stockholders will be approximately $7.6 million, or $0.34 per share of our common stock. However, the amounts to be distributed to our stockholders may be less if we incur greater liabilities than anticipated in winding down our affairs and/or less revenue than anticipated through the closing of the Asset Sale. (Alternatively, it is possible that we could distribute more than currently estimated if liabilities are less than expected and/or revenues are greater than expected.) A key factor in maximizing potential distributions is the timing of the closing of the Asset Sale, which is subject to certain risks and uncertainties. To the extent the closing of the Asset Sale is delayed beyond April 2009, we anticipate incurring additional operating expenses of up to $1 million per month to operate the Company through closing.

The following is a current estimate of cash assets and liabilities, and net available funds to distribute to stockholders, that will be available following the sale of substantially all of the Company’s assets to Zoll, such amounts being only estimates and subject to risks and uncertainties, such as unknown liabilities and claims, and the extent to which accounts receivable can be collected, that may significantly vary the amount, ultimately available to distribute to stockholders:

Assets

Proceeds of Asset Sale	$12.0 million
Zoll Purchase Order	$ 3.0 million
Cash & equivalents at closing	$ 2.0 million
Collections on A/R	$ 2.0 million
Total Assets	$19.0 million

Liabilities

Debt to GE (secured lender)	$ 3.7 million
Accounts Payable	$ 1.4 million
Wind down Liabilities	$ 6.3 million
Total Liabilities	$11.4 million

Net Available for Distribution	$7.6 million
($0.34 per share based on 22,400,000 fully-diluted shares)

The following highlights certain significant expenses that will be incurred in connection with the winding down of the Company’s affairs.

Severance Benefits

The amount of severance benefits payable to our officers and other employees pursuant to their employment agreements or our severance plan is $1.4 million, plus $0.1 million of associated payroll taxes. Pursuant to our Change in Control Plan, Vice Presidents will receive six months' base salary and continuation of benefits, and Director level employees will receive three months' base salary and continuation of benefits. Other employees are typically given up to one month's base pay as severance. Mr. Worthen, our CEO, will receive twelve months' base salary and continuation of benefits pursuant to his employment agreement. In addition, all restricted stock units ("RSUs") granted to current employees will vest upon the consummation of the Asset Sale, and each holder will receive the same distribution per share as stockholders. The following is a summary of the RSUs that have been granted to our executive officers:

Executive Officer	# of RSUs
William Worthen	425,000
Suzanne Winter	160,500
H. Michael Ameli	67,625

Lease Termination Costs

We lease office space for our corporate headquarters and operations in Irvine, California, consisting of approximately 27,000 square feet. The term of the lease ends in December 2011. As of December 31, 2008, our minimum future lease payments were approximately $1.4 million (including rent and related common area expenses). As of June 1, 2009, the anticipated date to vacate our facilities assuming the Asset Sale is consummated and the Plan of Dissolution is implemented, the remaining rental expense under the lease through the end of its term is anticipated to be approximately $1.2 million (including rent and related common area expenses).

We intend to negotiate to terminate the lease with our landlord. We currently do not know the amount of money we will be required to pay to terminate. We are currently trying to locate a tenant to replace us at our facility and have the landlord release us from all future lease obligations. In this case, the new tenant will likely pay lower rent than we do and we will have to pay the landlord some or all of the shortfall between our rent and that of the new tenant in order to secure a release of our lease obligations. If we are unable to negotiate termination of our lease at acceptable terms, we may seek to sublease our corporate headquarters facility, which would require landlord consent, and may require that we remain obligated in the event the subtenant defaults on the lease. This may require that we hold amounts in reserve during the lease term to cover potential liabilities. We do not know whether we would be successful in identifying a subtenant and negotiating a sublease on acceptable terms, or if successful, how long it would take to complete such a transaction.

Long-term debt

The senior secured credit facility with Merrill Lynch Capital (now GE Capital), entered into in February 2007 and amended in May 2007, consists of a $10.0 million term loan with an interest rate of one month LIBOR plus 6.50%, and the outstanding balance at December 31, 2008 is $3.7 million. The term loan requires interest only payments for the first six months and interest and principal payments for each month thereafter through February 2010. Based on the current interest rate at December 31, 2008, we estimate that our interest payments for fiscal 2009 will be $206 and in fiscal 2010 until maturity will be $6. As of our filing date, we owed a total of $2.9 million to GE Capital. In connection with the closing of the Asset Sale, we intend to repay GE Capital in full in the amount of $3.1 million which consists of principal and estimated accrued interest and fees through the closing. In April 2008, we entered into a new equipment financing agreement for $51 which requires monthly payments through April 2011. We intend to terminate this agreement at the closing of the Asset Sale and expect to pay a termination fee of $39.

Capital leases

In June 2006, we entered into a new lease commitment for computer equipment over a period of 63 months for a total value of $106. In November 2006, we entered into a new lease commitment for office equipment over a period of 60 months for a total value of $14. In April 2007, we entered into a new lease commitment for machinery and equipment over a period of 48 months for a total value of $14. We intend to terminate these leases at the closing of the Asset Sale and expect to pay termination fees of $82.

Uncertain Tax Liabilities

At December 31, 2008, we had uncertain tax positions which ultimately could result in a tax payment. We have agreed to sell substantially all of our assets to Zoll, which may result in a gain on the sale of our assets and a required tax payment to the State of California, due to their discontinuation of allowing NOLs to be recognized in asset sales. If a tax payment is owed to the State of California, it would reduce the funds available for distribution to shareholders.

Off-Balance Sheet Arrangements

Since inception, we have not engaged in material off-balance sheet activities, including the use of structured finance, special purpose entities or variable interest entities.

Recent Accounting Pronouncements

In September 2006, the FASB issued SFAS No. 157, Fair Value Measurements , which defines fair value, establishes a framework for consistently measuring fair value under generally accepted accounting principles, and expands disclosures about fair value measurements. SFAS 157 does not require any new fair value measurements, but provides guidance on how to measure fair value by providing a fair value hierarchy used to classify the source of the information. In February 2008, the FASB deferred the effective date of SFAS 157 by one year for certain nonfinancial assets and liabilities, except those that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually) to fiscal years beginning after November 15, 2008.

The fair value hierarchy described by the standard is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value and include the following:

Level 1 – Quoted prices in active markets for identical assets or liabilities.

Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

In accordance with SFAS 157, the following table represents the fair value hierarchy for our financial assets (cash equivalents and investments) measured at fair value on a recurring basis as of December 31, 2008:

	Fair Value Measurements Using
	Level 1		Level 2		Level 3		Total
Cash and cash equivalents	$	5,605		—		—	$	5,605

The adoption of SFAS 157 related to financial assets and liabilities did not have a material effect on our consolidated financial position, results of operations or cash flows. The book values of cash and cash equivalents, accounts receivable and accounts payable approximate their respective fair values due to the short-term nature of these instruments. We are currently evaluating the impact, if any, that SFAS 157 may have on our future consolidated financial statements related to nonfinancial assets and liabilities.

Effective September 30, 2008, we adopted Financial Staff Position No. SFAS 157-3, “Determining the Fair Value of a Financial Asset When the Market for That Asset is Not Active” (FSP SFAS 157-3), which was issued on October 10, 2008. FSP SFAS 157-3 clarifies the application of SFAS No. 157 in a market that is not active and provides an example to illustrate key considerations in determining the fair value of a financial asset when the market for the financial asset is not active. The adoption of FSP SFAS 157-3 did not have an impact on our consolidated financial statements.

In February 2007, the FASB issued SFAS No. 159, The Fair Value Option for Financial Assets and Financial Liabilities — Including an Amendment of SFAS No. 115. SFAS No. 159 provides reporting entities an option to measure certain financial assets and liabilities and other eligible items at fair value on an instrument-by-instrument basis. Unrealized gains and losses on items for which the fair value option has been elected are reported in earnings at each subsequent reporting date. SFAS No. 159 is effective for fiscal years beginning after November 15, 2007. The adoption of SFAS No. 159 did not have an impact on our consolidated financial position, results of operations and cash flows.

In December 2007, the FASB issued SFAS No. 141(R), Business Combinations. SFAS No. 141(R) requires reporting entities to record fair value estimates of contingent consideration and certain other potential liabilities during the original purchase price allocation, expense acquisition costs as incurred and does not permit certain restructuring activities previously allowed under EITF 95-3 to be recorded as a component of purchase accounting. In addition, under SFAS No. 141(R), changes in an acquired entity’s deferred tax assets and uncertain tax positions after the measurement period will impact income tax expense. SFAS No. 141(R) is effective for fiscal periods beginning after December 15, 2008 and should be applied prospectively for all business acquisitions entered into after the date of adoption. We do not expect the adoption of SFAS No. 141(R) to have an impact on our consolidated financial position, results of operations and cash flows.

In December 2007, the FASB issued SFAS No. 160, Noncontrolling Interest in Consolidated Financial Statements — an amendment of ARB No. 51. SFAS No. 160 requires (i) that noncontrolling (minority) interests be reported as a component of shareholders’ equity, (ii) that net income attributable to the parent and to the noncontrolling interest be separately identified in the consolidated statement of operations, (iii) that changes in a parent’s ownership interest while the parent retains its controlling interest be accounted for as equity transactions, (iv) that any retained noncontrolling equity investment upon the deconsolidation of a subsidiary by initially measured at fair value, and (v) that sufficient disclosures are provided that clearly identify and distinguish between the interests of the parent and the interests of the noncontrolling owners. SFAS No. 160 is effective for fiscal periods beginning after December 15, 2008. We are currently evaluating the impact the adoption of SFAS No. 160 will have on our consolidated financial position, results of operations and cash flows.

In March 2008, the FASB issued SFAS No. 161, Disclosures about Derivative Instruments and Hedging Activities – an amendment of FASB Statement No. 133. The new standard is intended to improve financial reporting about derivative instruments and hedging activities by requiring enhanced disclosures to enable investors to better understand their effects on an entity’s financial position, financial performance, and cash flows. Entities are required to provide enhanced disclosures about: (a) how and why an entity uses derivative instruments; (b) how derivative instruments and related hedged items are accounted for under SFAS No. 133 and its related interpretations; and (c) how derivative instruments and related hedged items affect an entity’s financial position, financial performance, and cash flows. This standard is effective for financial statements issued for fiscal years and interim periods beginning after November 15, 2008, with early application encouraged. We are currently evaluating the impact, if any, SFAS No. 161 will have on our consolidated financial position, results of operations or cash flows.

In March 2007, the FASB ratified Emerging Issues Task Force Issue 06-11, Accounting for Income Tax Benefits of Dividends on Share-Based Payment Awards, (“EITF Issue 06-11”). Beginning January 1, 2008, we adopted EITF Issue 06-11. In accordance with the EITF Issue, we record a credit to additional paid-in capital for tax deductions resulting from a dividend payment on non-vested share awards we expect to vest. The adoption of EITF Issue 06-11 did not have any impact on our consolidated financial statements.

In June 2008, the FASB issued Financial Accounting Standards Board Staff Position EITF 03-6-1, Determining Whether Instruments Granted in Share-Based Payment Transactions Are Participating Securities (“FSP 03-6-1”). The FSP provides that unvested share-based payment awards that contain nonforfeitable rights to dividends or dividend equivalents (whether paid or unpaid) are participating securities and shall be included in the computation of earnings per share pursuant to the two-class method in accordance with SFAS 128, Earnings per Share. The FSP is effective for financial statements issued for fiscal years beginning after December 15, 2008, and interim periods within those years. Upon adoption, we are required to retrospectively adjust our earnings per share data to conform with the provisions in this FSP. Early application of this FSP is prohibited. We are currently evaluating the impact that FSP 03-6-1 will have on our consolidated financial statements.

Critical Accounting Policies

Our discussion and analysis of our financial condition and results of operations is based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of financial statements requires management to make estimates and judgments that affect the reported amounts of assets and liabilities, revenue and expenses, and disclosures of contingent assets and liabilities as of the date of the financial statements. On a periodic basis, we evaluate our estimates, including those related to revenue recognition, accounts receivable, inventories, warranty, stock-based compensation, warrants and embedded derivatives. We use historical experience and other assumptions as the basis for making estimates. Actual results could differ from those estimates under different assumptions or conditions. We believe the following critical accounting policies affect our more significant judgments and estimates used in the preparation of our financial statements.

Revenue. We generate revenue primarily from the sale of our CoolGard and Thermogard systems, five families of single-use catheters and single-use start-up kits, one of which is required with each catheter used. In the United States, we have been selling our products through a direct sales force and are paid directly by the hospital purchasing our products. Outside of the United States, we have been selling our products to distributors at a discount to the list price and are paid directly by the distributor, who then sells to the hospital. Our revenue recognition policy is the same for both domestic customers and distributors.

We recognize revenue in accordance with SEC Staff Accounting Bulletin No. 104, Revenue Recognition, which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred and title and the risks and rewards of ownership have been transferred to the customer or services have been rendered; (3) the price is fixed or determinable; and (4) collectability is reasonably assured. Persuasive evidence of an arrangement consists of a purchase order for domestic customers and a distributor agreement with a purchase order for sales to international distributors. Delivery has occurred and title and the risks and rewards of ownership are transferred to the customer when the product has been shipped or received by the customer in accordance with the terms of the related purchase order. The price is fixed and determinable upon the receipt of a customer purchase order, which includes a stated purchase price. The majority of our arrangements include FOB shipping point terms. We use judgment when determining whether collection is reasonably assured and rely on a number of factors, including past transaction history with the customer and management evaluations of the credit worthiness of the customer. If we determine that collection is not reasonably assured, we would defer revenue until such time that collection is reasonably assured.

We evaluate whether the separate deliverables in its arrangements can be unbundled. Sales of the CoolGard and Thermogard systems domestically to hospitals include separate deliverables consisting of the CoolGard or Thermogard system, disposables used with the system and installation. For these sales, we apply the residual value method in accordance with Emerging Issues Task Force (“EITF”) No. 00-21, Revenue Arrangements with Multiple Deliverables, which requires the allocation of the total arrangement consideration less the fair value of the undelivered element, which consists of installation, to the delivered elements. Through December 31, 2008, there was a limited number of the undelivered element, resulting in a minimal amount attributed to the undelivered element.

Explicit return rights are not offered to customers; however, we may accept returns in limited circumstances. We do not offer return rights for expired products to our customers. We assess levels of inventory in the distribution channel through regular communications with distributors by international sales and service personnel. The amount of returns through December 31, 2008 has been minimal. A sales return allowance has not been established because we believe returns will be insignificant.

We enter into equipment loan agreements with stated terms of primarily six-months with certain customers whereby the CoolGard or Thermogard system is placed at the customer’s site for their evaluation and use. During this time, the customer purchases disposables. There are no stated minimum purchase requirements. We account for these arrangements in accordance with SFAS No. 13, Accounting for Leases, and have classified these arrangements as operating leases. The consideration for the rental portion of the arrangement is considered to be contingent and is recorded when earned. We currently do not charge a rental fee during the evaluation period. The amount of revenue attributable to the lease element of these arrangements was less than 10% of the Company’s total revenue for all periods presented. The CoolGard or Thermogard system is classified as evaluation equipment on the balance sheet and is depreciated over its estimated economic life of five years with depreciation included as a component of cost of revenue.

During 2005, we began to offer extended warranty contracts, which are separately sold to non-distributor customers. Revenue is recorded on a straight-line basis over the period of the contract, which is one year.

Accounts receivable. We record accounts receivable based on the invoice amount and do not charge interest on outstanding balances. Allowances for doubtful accounts are estimated for losses resulting from the inability of our customers to make required payments. We analyze accounts receivable and historical bad debts, customer credit, current economic trends and changes in customer payment trends when evaluating the adequacy of the allowance for doubtful accounts. Account balances are charged-off against the allowance when it is determined that the receivable will not be recovered. Different estimates regarding the collectability of accounts receivable may have a material impact on the timing and amount of reported bad debt expense and on the carrying value of accounts receivable. Zoll will not be acquiring our accounts receivable in connection with the Asset Sale.

Inventory. Inventory, consisting of finished goods, work-in-progress and raw materials is stated at the lower of cost (first-in, first-out) or market. Inventory reserves are established when conditions indicate that the selling price could be less than cost due to physical deterioration, usage, obsolescence, reductions in estimated future demand and reductions in selling prices. Our catheters have an expiration date of two years from the date of manufacture, which we have established based on safety standards. We balance the need to maintain strategic inventory levels with the risk of obsolescence due to changing technology and customer demand levels. Different estimates regarding the net realizable value of inventories could have a material impact on reported net inventory and costs of sales, and thus could have a material impact on the financial statements as a whole. Zoll will be acquiring all of inventory in connection with the Asset Sale.

Warranty reserve. We provide a 12 month warranty from date of purchase for domestic customers and a 15 month warranty from date of purchase for distributors on our CoolGard and Thermogard systems, which covers parts, labor and shipping costs. We also allow our domestic customers one year from the date of purchase and our distributors two years from the date of purchase or the expiration date, whichever is shorter, to exchange any catheter or start-up kit that contains a defect. Accordingly, we have established a warranty reserve for our products. We estimate the costs that may be incurred under the warranties and record a liability for the amount of such costs at the time the products are sold. Factors that affect the warranty liability include the number of units sold, historical and anticipated rates of warranty claims, and costs per claim, which requires management to make estimates about future costs. We periodically assess the adequacy of the recorded warranty liabilities and adjust the amounts as necessary. Although we test our products in accordance with our quality programs and processes, the warranty obligation is affected by product failure rates and service delivery costs incurred in correcting a product failure. Revisions to the originally estimated warranty liability would be required should actual product failure rates or service costs differ from original estimates, which are based on historical data. Differences could result in the amount of the recorded warranty liability and cost of sales if we made different judgments or used different estimates. Zoll will be assuming the warranty obligations for our business in connection with the Asset Sale.

Stock-based compensation. We applied the principles of Accounting Principles Board (“APB”) Opinion No. 25, Accounting for Stock Issued to Employees prior to January 1, 2006, which requires us to record compensation expense equal to the excess of the estimated fair value of our common stock over the employee option’s exercise price on the grant date, the intrinsic value, and record such compensation expense over the stock option’s vesting period. Effective January 1, 2006, we adopted the provisions of SFAS 123(R) using the prospective transition method. Under the prospective transition method, only new awards, or awards that have been modified, repurchased or cancelled after January 1, 2006, are accounted for using the fair value method. We will continue to account for awards outstanding as of January 1, 2006 using the accounting principles under APB No. 25. We also issue stock options to non-employees and apply the principles of EITF No. 96-18, Accounting for Equity Instruments that Are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services, which requires that such equity instruments are recorded at their fair value and periodically adjusted as the stock options vest. The fair value of our non-employee stock options is estimated using the Black-Scholes option pricing model, which requires the use of management’s judgment in estimating the inputs, including the expected term of the stock-based awards, stock price volatility, and pre-vesting forfeitures, used to determine fair value. Management’s estimate of the fair value of our common stock impacts compensation expense recorded in the results of operations for both employees and non-employees.

Another variable that impacts the estimated fair value of both our employee and nonemployee stock options granted after January 1, 2006 is the volatility of the common stock. Prior to the completion of the merger with Ithaka in June 2007, Alsius Medical’s common stock was not publicly traded. Therefore estimates were based on the volatility of comparable public companies for stock options granted after January 1, 2006. Changes in these estimates may impact the estimated value of the non-employee stock options and the related compensation expense recorded in the statement of operations.

In determining exercise prices for stock options prior to the merger with Ithaka in June 2007, we did not obtain contemporaneous valuations by an unrelated valuation specialist, but instead relied on our board of directors, the members of which we believe have extensive experience in the medical device market and a majority of which is comprised of non-employee directors, to determine a reasonable estimate of the then-current fair value of the common stock. Because we did not have any outside equity financings since September 2004, and because there had been no liquidity in our common stock, our board of directors determined the fair value of the common stock on the date options were granted based on several factors, including the liquidation preferences of our preferred stock, progress against regulatory and product development milestones, our financial condition and the likelihood of achieving a liquidity event such as an initial public offering or a sale of the company.

During the first six months of 2006, as we considered an initial public offering, we reassessed the valuations of common stock relating to option grants during the year ended December 31, 2005. We considered the expected value of our common stock in a planned initial public offering, in addition to our increasing sales, and favorable valuations of comparable publicly-traded medical device companies. As a result, the estimated fair value of our common stock in 2005 was greater than the exercise price of the stock options. We used a market-based approach in determining the fair value of our common stock as of each grant date, and also considered the following factors:

●

successive quarters of increased U.S. and international sales during 2005, which, by the end of the first six months of 2006 we believed evidenced its commercial traction;

●

our progress in developing its U.S. and international sales and marketing infrastructure;

●

our growing installed base of systems in hospitals and increasing catheter utilization; and

●

increased receptivity of the public capital markets to early stage medical device initial public offerings.

During the third quarter of 2006, as we changed our strategy from pursuing an initial public offering of our common stock to entering into a merger transaction with Ithaka, we reassessed the valuation model used in determining the fair value of common stock from a market-based approach to a probability weighted approach for a sale transaction or a recapitalization event. These new approaches included the following factors:

●

the proposed merger terms whereby eight million shares of Ithaka common stock would be issued as consideration for the merger;

●

the potential of an additional six million shares of Ithaka common stock would be issued as Milestone Shares if certain revenue targets were achieved in fiscal 2007-2009;

●

the amount of unsecured promissory notes which would have to be satisfied in accordance with their terms prior to any consideration being issued to our shareholders; and

●

the priority position of preferred stockholders, particularly the Series F preferred stockholders, to common stockholders.

After consideration of the above factors, we determined that the estimated fair value of our common stock since September 30, 2006 was minimal. We have not granted any stock options since May 2008.

Effective January 1, 2006, we account for stock options granted using SFAS No. 123(R), Share-Based Payment, which has replaced SFAS No. 123 and APB 25. Under SFAS No. 123(R), companies are no longer able to account for share-based compensation transactions using the intrinsic method in accordance with APB 25, we are currently accounting for such transactions using a fair-value method and are recognizing the expense in the statements of operations. We adopted the provisions of SFAS 123(R) using the prospective transition method. Under the prospective transition method, only new awards, or awards that have been modified, repurchased or cancelled after January 1, 2006, are accounted for using the fair value method.

Warrants. We issued warrants in 2005, 2006 and during the six months ended June 30, 2007 in connection with certain borrowings. We applied the principles of FSP 150-5, Issuer’s Accounting under FASB Statement No. 150 for Freestanding Warrants and Other Similar Instruments on Shares that are Redeemable, to record the warrants as liabilities based on their estimated value on the issuance date. The warrant is carried at its fair value with decreases or increases in fair value at each reporting date recorded as other income (expense). The fair value of the warrants is estimated using the Black-Scholes pricing model, which requires the use of management’s judgment in estimating the inputs, including the expected term of the warrant stock and price volatility, used to determine fair value. If actual results differ significantly from these estimates other income (expense) and our results of operations could be materially impacted.

Embedded Derivatives. In 2006 and during the three months ended March 31, 2007, we issued certain promissory notes (the “2006 Bridge Notes”). The 2006 Bridge Notes provide for a payment equal to 150% of the principal and accrued interest in the event there is a sale transaction of substantially all of the assets of the Company or a change in control in the form of the acquirer’s stock. This provision was determined to be an embedded derivative and was valued separately from the notes. The estimated fair value is determined using a present value analysis and management’s estimate of the probability of a sale transaction. The embedded derivative was recorded as a liability at its estimated fair value with decreases or increases in fair value at each reporting date recorded as other income (expense). If actual results differ significantly from these estimates other income (expense) and our results of operations could be materially impacted.

Income Taxes. Effective January 1, 2007, we adopted FASB Interpretation No. 48 (“FIN 48”), Accounting for Uncertainty in Income Taxes, which clarifies the accounting for uncertainty in income taxes recognized in the financial statements in accordance with FASB Statement No. 109, Accounting for Income Taxes. FIN 48 provides guidance on the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. FIN 48 also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosures, and transition. In accordance with FIN 48, a tax position is a position in a previously filed tax return or a position expected to be taken in a future tax filing that is reflected in measuring current or deferred income tax assets and liabilities. Tax positions are recognized only when it is more likely than not (likelihood of greater than 50%), based on technical merits, that the position will be sustained upon examination. Tax positions that meet the more likely than not threshold should be measured using a probability weighted approach as the largest amount of tax benefit that is greater than 50% likely of being realized upon settlement. The adoption of FIN 48 did not have a material impact on our financial position, results of operations or cash flows.

Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Substantially all of our revenue is denominated in U.S. dollars, including sales to our international distributors. Only a small portion of our revenue and expenses is denominated in foreign currencies, principally the Euro. Our Euro expenditures primarily consist of the cost of maintaining our office in the Netherlands, including the facility and employee-related costs. A 10% increase in the value of the U.S. dollar relative to the Euro or a 10% decrease in the relative value of the dollar would have a negligible impact on current costs or revenue. To date, we have not entered into any hedging contracts. Future fluctuations in the value of the U.S. dollar may, however, affect the price competitiveness of our products outside the United States.

We invest our excess cash primarily in a money market fund which invests in U.S. Treasury securities. We do not utilize derivative financial instruments, derivative commodity instruments or other market risk-sensitive instruments, positions or transactions to any material extent. Accordingly, we believe that, while the instruments we hold are subject to changes in the financial standing of the issuer of such securities, we are not subject to any material risks arising from changes in interest rates, foreign currency exchange rates, commodity prices, equity prices or other market changes that affect market risk sensitive instruments. Due to the short-term nature of these investments, a 1% change in market interest rates would not have a significant impact on the total value of our portfolio as of December 31, 2008.

Item 8.

Financial Statements and Supplementary Data

ALSIUS CORPORATION

CONSOLIDATED BALANCE SHEETS

(in thousands, except share data)

	December 31, 2008			December 31, 2007
ASSETS
Current Assets:
Cash and cash equivalents	$	5,605		$	24,427
Accounts receivable, net of allowances of $21 (2008) and $44 (2007)		2,958			2,162
Inventories		5,810			6,680
Prepaid expenses		388			284
Total current assets		14,761			33,553
Property and equipment, net		1,045			1,034
Evaluation equipment, net		1,056			673
Other assets		212			342
TOTAL	$	17,074		$	35,602

LIABILITIES AND SHAREHOLDERS’ EQUITY
Current Liabilities:
Accounts payable	$	2,113		$	2,732
Accrued liabilities		1,724			1,916
Current portion of long-term debt		3,216			3,200
Current portion of capital lease obligations		27			25
Total current liabilities		7,080			7,873
Long-term debt—less current portion		506			3,569
Capital lease obligations—less current portion		55			82
Other liabilities		65			66

Commitments and Contingencies (Note 11)


Shareholders’ Equity :
Preferred stock, $0.0001 par value—1,000,000 shares authorized; no shares issued or outstanding		—			—
Common stock, $0.0001 par value—75,000,000 shares authorized; 21,076,134 and 18,253,500 shares issued and outstanding at December 31, 2008 and December 31, 2007, respectively		2			2
Additional paid-in capital		126,233			122,237
Accumulated deficit		(116,867	)		(98,227	)
Total shareholders’ equity		9,368			24,012
TOTAL	$	17,074		$	35,602

See accompanying notes to consolidated financial statements.

ALSIUS CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except share and per share data)

	Year Ended December 31,
	2008			2007			2006

Revenue	$	12,461		$	9,114		$	5,979
Cost of revenue		9,089			7,341			6,167

Gross margin (loss)		3,372			1,773			(188	)

Operating expenses:
Research and development		4,234			3,920			2,948
Sales and marketing		12,373			11,211			6,045
General and administrative		4,992			5,471			4,352
Total operating expenses		21,599			20,602			13,345

Loss from operations		(18,227	)		(18,829	)		(13,533	)

Interest income		247			708			76
Interest expense		(660	)		(4,149	)		(2,064	)
Other income (expense)		—			35			(2,057	)

Net loss	$	(18,640	)	$	(22,235	)	$	(17,578	)

Net loss per share – basic and diluted	$	(0.89	)	$	(1.49	)	$	(1.60	)

Weighted average shares outstanding - basic and diluted		20,914,180			14,873,916			10,974,100

See accompanying notes to consolidated financial statements.

ALSIUS CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

	Year Ended December 31,
	2008			2007			2006
Cash flows from operating activities
Net loss	$	(18,640	)	$	(22,235	)	$	(17,578	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		649			421			378
Loss on disposal of assets		8			7			—
Increase (decrease) in fair value of warrant liabilities and embedded derivatives		—			(38	)		2,058
Amortization of debt issuance costs		37			62			81
Amortization of discounts on promissory notes		112			2,684			1,241
Stock-based compensation		3,549			3,387			574
Provision for bad debt expense		44			31			2
Changes in operating assets and liabilities, net of merger:
Accounts receivable		(840	)		(676	)		(534	)
Inventories		870			(4,312	)		(556	)
Prepaid expenses		(104	)		(50	)		(60	)
Other assets		51			164			(231	)
Accounts payable		(621	)		(919	)		1,721
Accrued liabilities		(193	)		773			1,026
Net cash used in operating activities		(15,078	)		(20,701	)		(11,878	)

Cash flows from investing activities
Cash paid for property and equipment		(344	)		(650	)		(109	)
Cash paid for evaluation equipment		(697	)		(259	)		(189	)
Restricted cash		34			—			—
Net cash received in merger		—			41,478			—
Net cash (used in) provided by investing activities		(1,007	)		40,569			(298	)

Cash flows from financing activities
Proceeds from exercise of common stock options		—			—			7
Payment of debt issuance costs		—			(347	)		—
Common stock warrant retirement		—			(167	)		—
Common stock warrant repurchases		—			(907	)		—
Proceeds from warrant retirement program, net		447			—			—
Proceeds from issuance of long-term debt		51			13,030			9,070
Principal payments under long-term debt		(3,210	)		(7,675	)		(1,534	)
Principal payments under capital lease obligations		(25	)		(22	)		(29	)
Net cash (used in) provided by financing activities		(2,737	)		3,912			7,514

Net increase (decrease) in cash and cash equivalents		(18,822	)		23,780			(4,662	)
Cash and cash equivalents at beginning of year		24,427			647			5,309

Cash and cash equivalents at end of year	$	5,605		$	24,427		$	647

Cash paid during the year for:
Income taxes	$	4		$	85		$	1
Interest	$	545		$	862		$	426

Non-cash transactions
Unpaid property and equipment included in accounts payable	$	2		$	208		$	—
Property and equipment acquired under capital lease	$	—		$	14		$	124

See accompanying notes to consolidated financial statements.

ALSIUS CORPORATION

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT)

(in thousands, except share data)

	Common Stock
	Shares			Amount			Additional Paid In Capital			Deferred Stock- Based Compensation			Accumulated Deficit			Total
Balances as of January 1, 2006		56,984		$	16,147		$	—		$	(1,091	)	$	(58,414	)	$	(43,358	)
Exercise of stock options		21,958			7												7
Compensation for non-employee stock options					(47	)											(47	)
Stock-based compensation					323												323
Amortization of stock-based compensation											298						298
Net loss														(17,578	)		(17,578	)
Balances as of December 31, 2006		78,942			16,430			—			(793	)		(75,992	)		(60,355	)

Amortization of stock-based compensation											141						141
Stock-based compensation					88												88
Elimination of Alsius historical equity accounts		(78,942	)		(16,518	)		16,518									—
Elimination of deferred stock-based compensation								(652	)		652						—
Conversion of preferred stock into Merger Shares		4,902,527			1			46,669									46,670
Conversion of Bridge Notes and accrued interest into Merger Shares		3,097,473						17,036									17,036
Equity effects of reverse merger		10,974,100			1			44,445									44,446
Reclassification of warrant liability to equity								215									215
Common stock warrant repurchase program								(907	)								(907	)
Common stock warrant retirement program								(167	)								(167	)
Redemption of redeemable common stock		(720,600	)					(4,078	)								(4,078	)
Stock-based compensation (SFAS 123R)								3,158									3,158
Net loss														(22,235	)		(22,235	)
Balances as of December 31, 2007		18,253,500			2			122,237			—			(98,227	)		24,012
Common stock warrant retirement program, net of costs of $437		2,822,634						447									447
Stock-based compensation (SFAS 123R)								3,549									3,549
Net loss														(18,640	)		(18,640	)
Balances as of December 31, 2008		21,076,134		$	2		$	126,233		$	—		$	(116,867	)	$	9,368

See accompanying notes to consolidated financial statements.

ALSIUS CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except share and per share data)

1. The Company and Basis of Presentation

On June 21, 2007, Ithaka Acquisition Corp., a Delaware corporation (“Ithaka”), completed its acquisition of Alsius Corporation, a privately held California corporation (“Alsius Medical”), through a merger of a wholly owned merger subsidiary with and into Alsius Medical. Ithaka was a publicly traded blank check company formed in 2005 to acquire an unidentified operating business in the healthcare industry. In the merger, Alsius Medical became a wholly owned subsidiary of Ithaka, and Ithaka changed its name to Alsius Corporation. As a result, Alsius Corporation succeeded Ithaka as the reporting registrant for purposes of this report. Alsius Corporation is now a publicly traded Delaware holding company operating through its wholly owned subsidiary, Alsius Medical Corporation. Alsius Corporation and its operating subsidiary are referred to collectively as “Alsius,” “we,” “us,” and the “Company”. Alsius Corporation’s common stock trades on NASDAQ under the symbol “ALUS”. See Note 3 for further details on the merger. For accounting purposes, the merger was treated as a reverse acquisition with Alsius Medical being the accounting acquirer. Therefore, the Company’s historical financial statements reflect those of Alsius Medical.

Alsius Medical was incorporated in December 1991, and recapitalized and reorganized its operations and business in November 1998 to focus on intravascular temperature management. In June 2001, a branch office, Alsius Service Center, in Wateringen, The Netherlands, was established to provide field support for its products in Europe. Alsius Medical develops, manufactures, markets and sells, proprietary catheter-based products for rapid cooling and temperature control of patients with severe neuronal injury, including those who have suffered stroke, traumatic brain injury and cardiac arrest. In August 2003, Alsius Medical received United States Food and Drug Administration (FDA) clearance to market its CoolGard ® 3000 Thermal Regulation System (the “CoolGard system”) and Cool Line ® catheter for use in fever control. In addition, in October 2003, Alsius Medical received FDA clearance to market its Icy ™, Fortius ™ , Quattro™ and Solex™ catheters in combination with the CoolGard ® 3000 Thermal Regulation System for use in normothermia in cardiac surgery and hypothermia in neuro surgery. Alsius Medical began to market and sell its products in the United States during the year ended December 31, 2004.

Going Concern

The Company has incurred significant net losses since inception, and has relied on its ability to obtain financing, which to date has been through a merger as discussed in Note 3, the sale of redeemable convertible preferred stock (Note 10) and the issuance of promissory notes (Note 5). Management expects operating losses and negative cash flows to continue for the foreseeable future as the Company incurs additional costs and expenses related to continued development of the Company’s products, and obtaining FDA approval for new indications. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements have been prepared on a going concern basis that contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The financial statements do not include adjustments relating to the recoverability of recorded asset amounts or the amounts or classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s ability to meet its obligations in the ordinary course of business is dependent upon its ability to establish profitable operations, or to secure other sources of financing to fund operations.

If the Asset Sale (as defined below) were not to be completed, the Company will not have sufficient financial resources to continue to operate independently, and would need to immediately raise funds or cease operations and liquidate.

Recent Developments

Asset Sale

On February 20, 2009, we announced that we signed an asset purchase agreement (the “Purchase Agreement”) on February 19, 2009 with Zoll Circulation, Inc. (“Zoll”), a wholly owned subsidiary of ZOLL Medical Corporation (Nasdaq: ZOLL), whereby we will sell substantially all our assets, including those constituting our intravascular temperature management device business, to Zoll for a purchase price of $12.0 million in cash (the “Asset Sale”). In connection with the Asset Sale, Zoll placed an order with the Company to purchase approximately $3 million of finished product at cost. The closing of the Asset Sale is subject to customary closing conditions, and is expected to close in the second quarter of fiscal 2009.

The record holders of a majority of the outstanding shares of the Company’s common stock signed a written consent to approve the Asset Sale. The Asset Sale is discussed in further detail in a draft information statement that we filed with the SEC. When the SEC review is complete, we will mail a definitive information statement (the "Information Statement") to our stockholders and, under applicable rules, can close the Asset Sale 20 days after the mailing.

Plan of Dissolution

On February 19, 2009, our Board also unanimously adopted a plan providing for the complete dissolution and liquidation of the Company (the “Plan of Dissolution”). The record holders of a majority of the outstanding shares of our common stock signed a written consent to adopt and approve the Plan of Dissolution.

ALSIUS CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except share and per share data)

If the Asset Sale is consummated, we will file a certificate of dissolution with the Delaware Secretary of State to dissolve the Company as a legal entity, complete the liquidation of the remaining assets, and satisfy (or make provisions to satisfy) remaining obligations.Pursuant to the Plan of Dissolution, after payment or provision for all the known, unascertained or contingent debts, obligations and liabilities of the Company (including costs and expenses incurred and anticipated to be incurred in connection with the Asset Sale and liquidation of the Company), payment or distributions will be made to the holders of our common stock. The potential timing and amount of distributions is discussed below under Liquidating Distributions. In the unexpected event all distributions have not occurred within three years of filing of the certificate of dissolution, our remaining assets will be transferred to a liquidating trust for the benefit of our stockholders, and a liquidation trustee will be assigned to administer the assets, settle liabilities, and make distributions to stockholders if and when funds are legally available for distribution.

As the Purchase Agreement was signed in 2009, these financial statements do not include adjustments that may result from this transaction relating to the classification and amounts of liabilities or assets that might be necessary once management begins to dissolve and liquidate the Company.

Liquidating Distributions

We anticipate that an initial distribution of liquidation proceeds will be made to our stockholders within 90 days after the closing of the Asset Sale. As we liquidate our remaining assets and pay off our outstanding liabilities, we will distribute additional liquidation proceeds, if any, to our stockholders as the Board deems appropriate. A final $1 million will be held in trust for one year from the closing date of the Asset Sale to cover potential indemnity obligations to Zoll under the Purchase Agreement for the Asset Sale. The amounts to be distributed to our stockholders may be less if we incur greater liabilities in winding down our affairs and/or less revenue than anticipated through the closing of the Asset Sale. (Alternatively, it is possible that we could distribute more if liabilities are less than expected and/or revenues are greater than expected.) A key factor in maximizing potential distributions is the timing of the closing of the Asset Sale, which is subject to certain risks and uncertainties. To the extent the closing of the Asset Sale is delayed beyond April 2009, we anticipate incurring additional operating expenses to operate the Company through the closing.

2. Significant Accounting Policies

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. The results of Ithaka are included in the consolidated financial statements since the date of the merger (June 21, 2007).

Management Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make certain estimates and assumptions. These affect the reported amounts of assets and liabilities and disclosure of contingent assets or liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Management has identified revenue, accounts receivable, inventory, warranty reserve, stock-based compensation, warrants, embedded derivatives and income taxes as areas where significant estimates and assumptions have been made in preparing the financial statements. The Company also evaluates the need for the deferred income tax valuation allowance.

Fair Value of Financial Instruments

Financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities. These instruments approximate fair value because of their short maturity. The carrying value of the long-term debt is considered to approximate fair value due to its short maturity and interest rate that approximates current rates.

ALSIUS CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except share and per share data)

Foreign Currency Remeasurement

The functional currency of the Company’s branch located in The Netherlands is the U.S. dollar. Its local currency statements are remeasured into U.S. dollars using the current exchange rate for monetary assets and liabilities and the historical exchange rate for nonmonetary assets and liabilities. Revenues and expenses are remeasured using the average exchange rate for the period, except items related to nonmonetary assets and liabilities, which are remeasured using historical exchange rates. All remeasurement gains and losses are included in determining net loss and have not been significant for all periods presented.

Cash Equivalents

The Company considers all highly liquid investments that mature within 90 days from the date of purchase to be cash equivalents. At December 31, 2008, cash equivalents consisted of money market funds of $5,263. At December 31, 2007, cash equivalents consisted of money market funds of $23,903.

Concentration of Risk

The Company maintains its cash accounts in a commercial bank. At December 31, 2008 and 2007, cash on deposit totaling $5,355 and $24,225, respectively, was in excess of the federally insured limits. Management does not believe this concentration subjects it to any unusual financial risk beyond the normal risk associated with commercial banking relationships.

Customers that account for greater than 10 percent of revenue or accounts receivable are provided below.

	Year Ended December 31,
	2008			2007			2006

	Revenue		Percent of Total Revenue	Revenue		Percent of Total Revenue	Revenue		Percent of Total Revenue
Customer A	$	—	—%	$	308	3%	$	1,449	24%
Customer B		2,846	23%		1,395	15%		—	—

	As of December 31,
	2008			2007
	Receivable Balance		Percent of Total Receivables	Receivable Balance		Percent of Total Receivables
Customer A	$	—	—%	$	29	1%
Customer B		523	18%		429	20%

Many of the components and materials used in the Company’s products are manufactured by a limited number of suppliers. Any supply interruption or an increase in demand beyond the suppliers’ capabilities could have an adverse impact on the Company’s business. There is one supplier for a key component used in the Company’s CoolGard and Thermogard systems, and one supplier for a key component used in the Company’s catheters.

Accounts Receivable

Accounts receivable are recorded at the invoiced amount and do not bear interest. The Company maintains allowances for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments. The Company specifically analyzes accounts receivable and historical bad debts, customer credit, current economic trends and changes in customer payment trends when evaluating the adequacy of the allowance for doubtful accounts. Account balances are charged-off against the allowance when it is determined that the receivable will not be recovered.

ALSIUS CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except share and per share data)

The changes in the allowance for doubtful accounts are provided below.

	Year Ended December 31,
	2008			2007		2006
Beginning balance	$	44		$	13	$	27
Provision for bad debt		44			31		2
Write-offs, net of recoveries		(67	)		—		(16	)
Ending balance	$	21		$	44	$	13

Inventories

Inventories are comprised of raw materials, work-in-process and finished goods, and are stated at the lower of cost (first-in, first-out) or market. The Company records a provision for excess and obsolete inventory based on historical usage and future product demand. Once established, the write-downs of inventories for excess and obsolete inventory are considered permanent adjustments to the cost basis of the inventories.

Long-lived Assets

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company evaluates potential impairment by comparing the carrying amount of the asset with the estimated undiscounted future cash flows associated with the use of the asset and its eventual disposition. Should the review indicate that the asset is not recoverable, the Company’s carrying value of the asset would be reduced to its estimated fair value, which is measured by future discounted cash flows. During the years ended December 31, 2008, 2007 and 2006 there have been no such impairments.

Property and Equipment

Property and equipment, including assets under capital leases, are carried at cost less accumulated depreciation and amortization. Depreciation and amortization are recorded on a straight-line basis over the estimated useful lives of the respective assets as follows:

Machinery and equipment	3 to 5 years
Computer equipment	3 years
Furniture and fixtures	5 years
Leasehold improvements	Shorter of the useful life of the improvements or the lease term

Leasehold improvements are amortized over the life of the remaining lease term. Expenditures for major renewals and betterments are capitalized, while minor replacements, maintenance and repairs, which do not extend the asset lives, are charged to operations as incurred. Upon sale or disposition, the cost and related accumulated depreciation and amortization are removed from the accounts and any gain or loss is included in operations.

Evaluation Equipment

Evaluation equipment consists of CoolGard and Thermogard systems placed at hospitals under the Company’s equipment loan agreements and are depreciated using the straight-line method over their estimated economic life of five years. As of December 31, 2008 and 2007 the cost of evaluation equipment was $1,708 and $1,109 and accumulated depreciation was $653 and $436, respectively. For the years ended December 31, 2008, 2007 and 2006, $314, $222 and $219, respectively, was recorded as a component of cost of revenue for the depreciation of the equipment.

ALSIUS CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except share and per share data)

Stock-Based Compensation

Effective January 1, 2006 the Company adopted Statement of Financial Accounting Standards (“SFAS”) No. 123(R), Share-Based Payment, which revises SFAS No. 123, Accounting for Stock-Based Compensation issued in 1995. Prior to the adoption of SFAS 123(R) the Company accounted for stock-based employee compensation arrangements using the intrinsic value method in accordance with the provisions and related interpretations of Accounting Principles Board Opinion No. 25, Accounting for Stock Issued to Employees (“APB No. 25”). The Company adopted SFAS 123(R) applying the “prospective transition method” under which it continues to account for nonvested equity awards outstanding at the date of adoption of SFAS 123(R) in the same manner as they had been accounted for prior to adoption, that is, it would continue to apply APB No. 25 in future periods to equity awards outstanding at the date it adopted SFAS 123(R).

As of December 31, 2006 there was $255 of unrecognized compensation cost related to nonvested share-based compensation arrangements granted under share-based compensation plans using the fair value method of SFAS 123(R). As of December 31, 2006, the cost was expected to be recognized over a weighted-average period of 3.05 years, using the graded vested attribution method. In the merger effective on June 21, 2007 (Note 3), due to the liquidation preferences of the Company’s redeemable convertible preferred stock and the terms and conditions of the Company’s Bridge Notes, all outstanding stock options of the Company were cancelled, therefore any unrecognized compensation related to nonvested share-based compensation arrangements was cancelled. Compensation cost of $88 was recognized for the year ended December 31, 2007 (for the period prior to June 21, 2007, the date of the merger). There were no stock option grants in the six months ended June 30, 2007. See Note 7 regarding stock option grants in the six months ended December 31, 2007 and in the year ended December 31, 2008.

Calculating stock-based compensation expense requires the input of subjective assumptions, including the expected term of the stock-based awards, stock price volatility, and pre-vesting option forfeitures. The estimate of expected term of options granted under the 2004 Plan was determined by analyzing historical data on employees’ stock option exercises. The estimate of expected term of options granted under the 2006 Plan was calculated using the simplified method, as prescribed in SEC Staff Accounting Bulletin No. 110. Prior to the merger with Ithaka in June 2007, the Company was a private entity with no historical data on volatility of its stock. Therefore, the expected volatility used was based on volatility of similar entities (referred to as “guideline companies”) for stock options granted after January 1, 2006. In evaluating similarity, the Company considered factors such as industry, stage of life cycle, size, and financial leverage. The assumptions used in calculating the fair value of stock-based awards represent the Company’s best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and the Company uses different assumptions, stock-based compensation expense could be materially different in the future. In addition, the Company is required to estimate the expected forfeiture rate and only recognize expense for those shares expected to vest. The Company estimates the forfeiture rate for options granted after January 1, 2006 under the 2004 Plan based on historical experience of its stock-based awards that are granted, exercised and cancelled. For options granted under the 2006 Plan, the forfeiture rate used was based on the estimated forfeiture rates of the guideline companies.

The risk-free rate for periods within the contractual life of the option is based on United States treasury yield for a term consistent with the expected life of the stock option in effect at the time of grant. The Company has never declared or paid any cash dividends and does not presently plan to pay cash dividends in the foreseeable future. Prior to the adoption of SFAS 123(R), the Company did not record any tax benefits resulting from the exercise of options due to uncertainty surrounding the timing of realizing the benefits of its deferred tax assets in future periods. The Company has elected to use the graded vesting attribution approach to record compensation expense. Shares of common stock issued upon exercise of stock options will be from previously unissued shares.

The weighted-average fair value per share of the options granted was $1.33, $3.33 and $3.98 for the years ended December 31, 2008, 2007 and 2006, respectively. The fair value of the stock options at the date of grant was estimated using the Black-Scholes option-pricing model with the following assumptions:

	Year Ended December 31, 2008		Year Ended December 31, 2007	Year Ended December 31, 2006
Dividend Yield		0.00%	0.00%		0.00%
Volatility		66%	67%		61%
Weighted-average risk-free interest rate		3.00%	4.89%		4.82%
Expected life	6.0-6.25 years		6.0-6.25 years	5.61-5.88 years

ALSIUS CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except share and per share data)

The Company accounts for equity instruments issued to nonemployees in accordance with the provisions of Emerging Issues Task Force No. 96-18, Accounting for Equity Instruments that are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services (“EITF 96-18”). Under EITF 96-18, stock option awards issued to nonemployees are accounted for at fair value using the Black-Scholes option pricing model. Management believes the fair value of the stock options is more reliably measurable than the fair value of services received. The fair value of each nonemployee stock award is remeasured each period until a commitment date is reached, which is the vesting date, using the attribution method in FASB Interpretation No. 28, Accounting for Stock Appreciation Rights and Other Variable Stock Option or Award Plans. For nonemployee awards, deferred stock-based compensation is not reflected in shareholders’ equity until a commitment date is reached.

SFAS 123 was replaced by SFAS 123(R); accordingly, the Company no longer follows SFAS 123 when accounting for nonemployee stock option, but continues to apply the principles of EITF 96-18. When specific guidance does not exist in EITF 96-18 for nonemployee stock options, the Company follows the principles of SFAS 123(R). There was no impact to the financial statements for nonemployee stock options as a result of the adoption of SFAS 123(R).

Revenue Recognition

The Company sells its products domestically to customers through its direct sales force, and internationally through distributors. Revenue is recognized in accordance with SEC Staff Accounting Bulletin No. 104, Revenue Recognition, which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred and title and the risks and rewards of ownership have been transferred to the customer or services have been rendered; (3) the price is fixed or determinable; and (4) collectibility is reasonably assured. Price protection, stock rotation rights and sales incentive programs are not offered to customers.

The Company evaluates whether the separate deliverables in its arrangements can be unbundled. Sales of the CoolGard and Thermogard systems domestically to hospitals include separate deliverables consisting of the product, disposables used with the CoolGard and Thermogard system and installation. For these sales, the Company applies the residual value method in accordance with EITF 00-21, Revenue Arrangements with Multiple Deliverables, which requires the allocation of the total arrangement consideration less the fair value of the undelivered element, which consists of installation, to the delivered elements. As of December 31, 2008, 2007 and 2006 there was a minimal amount attributed to the undelivered element.

Explicit return rights are not offered to customers; however, the Company may accept returns in limited circumstances. The amount of returns through December 31, 2008 has been minimal. A sales return allowance has not been established since management believes returns will be insignificant.

The Company enters into equipment loan agreements with stated terms of primarily six months with certain customers whereby the CoolGard or Thermogard system is placed at the customer’s site for their evaluation and use. During this time, the customer purchases disposables. There are no stated minimum purchase requirements. The Company accounts for these arrangements in accordance with SFAS No. 13, Accounting for Leases, and has classified these arrangements as operating leases. We currently do not charge a rental fee during the evaluation period. The amount of revenue attributable to the lease element of these arrangements was less than 10% of the Company’s total revenue for all periods presented. The CoolGard or Thermogard system is classified as evaluation equipment and is depreciated over its estimated economic life of five years with depreciation included as a component of cost of revenue.

The Company offers extended warranty contracts, which are separately sold to non-distributor customers. Revenue is recorded on a straight-line basis over the period of the contract, which is generally one year.

Product Warranty

The Company provides a 12 month warranty from the date of purchase for domestic customers and a 15 month warranty from the date of purchase for distributors on its CoolGard and Thermogard systems, which covers parts, labor and shipping costs. The Company will also accept returns for disposables with defects one year from the date of purchase for domestic customers and the shorter of two years or the expiration date of the disposables for distributors. Warranty costs are estimated at the time of sale based on historical experience. Estimated warranty expenses are recorded as an accrued liability, with a corresponding provision to cost of revenue.

ALSIUS CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except share and per share data)

Changes in the Company’s product warranty liability were as follows:

	Year Ended December 31,
	2008			2007			2006
Beginning balance	$	107		$	156		$	202
Provision for estimated warranty costs		48			79			185
Warranty expenditures		(78	)		(128	)		(231	)
Ending balance	$	77		$	107		$	156

Cost of Revenue

Cost of revenue consists of costs of materials, products purchased from third-parties, manufacturing personnel, freight, depreciation of property and equipment, royalties paid to technology licensors, manufacturing overhead, warranty expenses and inventory reserves. Royalties paid to third parties include two worldwide licenses related to our catheters. One license covers a coating used on our catheters and requires that we pay a royalty of between 2.0% and 3.5% on net revenue generated by all catheters. The other license covers technology used in our Cool Line catheter and requires that we pay a royalty of 2.5% on net revenue generated by the Cool Line catheter.

Shipping and Handling

Charges to customers for shipping and handling are included as a component of revenue. Shipping and handling costs are expensed as incurred and recorded as a component of cost of revenue.

Research and Development

Research and development expenses consist of engineering personnel salaries and benefits, prototype supplies, and consulting fees related to product development. Research and development costs are expensed as incurred.

Advertising

Advertising costs are expensed as incurred. Included in sales and marketing expense for the years ended December 31, 2008, 2007 and 2006 was $266, $682, and $275, respectively.

Income Taxes

We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

We record net deferred tax assets to the extent we believe these assets will more likely than not be realized. In making such determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations. In the event we were to determine that we would be able to realize our deferred income tax assets in the future in excess of their net recorded amount, we would make an adjustment to the valuation allowance which would reduce the provision for income taxes. We currently record a full valuation allowance as we do not believe it is more likely than not that our deferred tax assets will be realized.

Effective January 1, 2007, the Company adopted FASB Interpretation No. 48 (“FIN 48”), Accounting for Uncertainty in Income Taxes, which clarifies the accounting for uncertainty in income taxes recognized in the financial statements in accordance with FASB Statement No. 109, Accounting for Income Taxes. FIN 48 provides guidance on the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. FIN 48 also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosures, and transition. In accordance with FIN 48, a tax position is a position in a previously filed tax return or a position expected to be taken in a future tax filing that is reflected in measuring current or deferred income tax assets and liabilities. Tax positions are recognized only when it is more likely than not (likelihood of greater than 50%), based on technical merits, that the position will be sustained upon examination. Tax positions that meet the more likely than not threshold should be measured using a probability weighted approach as the largest amount of tax benefit that is greater than 50% likely of being realized upon settlement. The adoption of FIN 48 did not have a material impact on the Company’s consolidated financial position, results of operations or cash flows.

ALSIUS CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except share and per share data)

Net Loss Per Share

The merger with Ithaka, as discussed in Note 3, for financial reporting purposes was treated as a reverse acquisition. Because the number of shares outstanding following a reverse acquisition is significantly different from the number of shares outstanding prior to the combination, the weighted average shares outstanding for purposes of presenting net loss per share on a comparative basis has been retroactively restated to the earliest period presented in order to reflect the effect of the reverse acquisition. In effect, the reverse acquisition is similar to a stock split for the accounting acquirer, and retroactively restating the weighted average shares outstanding is consistent with the accounting required by SFAS No. 128, Earnings Per Share, for stock splits, stock dividends, and reverse stock splits.

Comprehensive Loss

For the years ended December 31, 2008, 2007 and 2006, there was no difference between the Company’s net loss and comprehensive loss.

New Accounting Pronouncements

Level 1 – Quoted prices in active markets for identical assets or liabilities.

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

In accordance with SFAS 157, the following table represents the Company’s fair value hierarchy for its financial assets (cash equivalents and investments) measured at fair value on a recurring basis as of December 31, 2008:

	Fair Value Measurements Using
	Level 1		Level 2		Level 3		Total
Cash and cash equivalents	$	5,605		—		—	$	5,605

The adoption of SFAS 157 related to financial assets and liabilities did not have a material effect on the Company’s consolidated financial position, results of operations or cash flows. The book values of cash and cash equivalents, accounts receivable and accounts payable approximate their respective fair values due to the short-term nature of these instruments. The Company is currently evaluating the impact, if any, that SFAS 157 may have on its future consolidated financial statements related to nonfinancial assets and liabilities.

ALSIUS CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except share and per share data)

Effective September 30, 2008, the Company adopted Financial Staff Position No. SFAS 157-3, “Determining the Fair Value of a Financial Asset When the Market for That Asset is Not Active” (FSP SFAS 157-3), which was issued on October 10, 2008. FSP SFAS 157-3 clarifies the application of SFAS No. 157 in a market that is not active and provides an example to illustrate key considerations in determining the fair value of a financial asset when the market for the financial asset is not active. The adoption of FSP SFAS 157-3 did not have an impact on the Company’s consolidated financial statements.

In February 2007, the FASB issued SFAS No. 159, The Fair Value Option for Financial Assets and Financial Liabilities — Including an Amendment of SFAS No. 115. SFAS No. 159 provides reporting entities an option to measure certain financial assets and liabilities and other eligible items at fair value on an instrument-by-instrument basis. Unrealized gains and losses on items for which the fair value option has been elected are reported in earnings at each subsequent reporting date. SFAS No. 159 is effective for fiscal years beginning after November 15, 2007. The adoption of SFAS No. 159 did not have an impact on the Company’s consolidated financial position, results of operations and cash flows as management did not elect the fair value option for any other financial instruments or any other financial assets and financial liabilities.

In December 2007, the FASB issued SFAS No. 141(R), Business Combinations. SFAS No. 141(R) requires reporting entities to record fair value estimates of contingent consideration and certain other potential liabilities during the original purchase price allocation, expense acquisition costs as incurred and does not permit certain restructuring activities previously allowed under EITF 95-3 to be recorded as a component of purchase accounting. In addition, under SFAS No. 141(R), changes in an acquired entity’s deferred tax assets and uncertain tax positions after the measurement period will impact income tax expense. SFAS No. 141(R) is effective for fiscal periods beginning after December 15, 2008 and should be applied prospectively for all business acquisitions entered into after the date of adoption. The Company does not expect the adoption of SFAS No. 141(R) to have an impact on its consolidated financial position, results of operations and cash flows.

In December 2007, the FASB issued SFAS No. 160, Noncontrolling Interest in Consolidated Financial Statements — an amendment of ARB No. 51. SFAS No. 160 requires (i) that noncontrolling (minority) interests be reported as a component of shareholders’ equity, (ii) that net income attributable to the parent and to the noncontrolling interest be separately identified in the consolidated statement of operations, (iii) that changes in a parent’s ownership interest while the parent retains its controlling interest be accounted for as equity transactions, (iv) that any retained noncontrolling equity investment upon the deconsolidation of a subsidiary by initially measured at fair value, and (v) that sufficient disclosures are provided that clearly identify and distinguish between the interests of the parent and the interests of the noncontrolling owners. SFAS No. 160 is effective for fiscal periods beginning after December 15, 2008. The Company does not currently expect the adoption of SFAS No. 160 to have a material impact on the Company’s consolidated financial position, results of operations and cash flows.

In March 2008, the FASB issued SFAS No. 161, Disclosures about Derivative Instruments and Hedging Activities – an amendment of FASB Statement No. 133. The new standard is intended to improve financial reporting about derivative instruments and hedging activities by requiring enhanced disclosures to enable investors to better understand their effects on an entity’s financial position, financial performance, and cash flows. Entities are required to provide enhanced disclosures about: (a) how and why an entity uses derivative instruments; (b) how derivative instruments and related hedged items are accounted for under SFAS No. 133 and its related interpretations; and (c) how derivative instruments and related hedged items affect an entity’s financial position, financial performance, and cash flows. This standard is effective for financial statements issued for fiscal years and interim periods beginning after November 15, 2008, with early application encouraged. The Company does not currently expect the adoption of SFAS No. 161 to have a material impact on the Company’s consolidated financial position, results of operations or cash flows.

In March 2007, the FASB ratified Emerging Issues Task Force Issue 06-11, Accounting for Income Tax Benefits of Dividends on Share-Based Payment Awards, (“EITF Issue 06-11”). Beginning January 1, 2008, the Company adopted EITF Issue 06-11. In accordance with the EITF Issue, the Company records a credit to additional paid-in capital for tax deductions resulting from a dividend payment on non-vested share awards the Company expects to vest. The adoption of EITF Issue 06-11 did not have any impact on the Company’s consolidated financial statements.

In June 2008, the FASB issued Financial Accounting Standards Board Staff Position EITF 03-6-1, Determining Whether Instruments Granted in Share-Based Payment Transactions Are Participating Securities (“FSP 03-6-1”). The FSP provides that unvested share-based payment awards that contain nonforfeitable rights to dividends or dividend equivalents (whether paid or unpaid) are participating securities and shall be included in the computation of earnings per share pursuant to the two-class method in accordance with SFAS 128, Earnings per Share. The FSP is effective for financial statements issued for fiscal years beginning after December 15, 2008, and interim periods within those years. Upon adoption, the Company is required to retrospectively adjust its earnings per share data to conform with the provisions in this FSP. Early application of this FSP is prohibited. The Company is currently evaluating the impact that FSP 03-6-1 will have on its consolidated financial statements.

ALSIUS CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except share and per share data)

3. Merger with Ithaka

On June 21, 2007, Ithaka’s stockholders approved the merger of Alsius Medical with and into Ithaka’s wholly owned merger subsidiary. The merger consideration consisted of 8,000,000 shares of Ithaka’s common stock (the “Merger Shares”) in exchange for all of the issued and outstanding equity securities of Alsius Medical. Of the 8,000,000 shares issued in consideration, 4,902,527 shares were issued to Alsius Medical preferred stock holders and 3,097,473 shares were issued to holders of Alsius Medical bridge notes. In addition, Alsius Medical’s shareholders also were given the right to receive up to 6,000,000 additional shares (the “Milestone Shares”) if the combined company meets certain revenue targets in fiscal years 2007 through 2009 (with 750,000 Milestone Shares allocated to 2007, 1,750,000 to 2008 revenues and 3,500,000 to 2009 revenues). In 2007 and 2008, the revenue targets were not met and no Milestone Shares were issued. Additionally, Ithaka agreed to fund bonuses totaling $3,000 to management, employees, two non-employee directors and certain consultants of Alsius Medical. The $3,000 bonus paid by Ithaka was included as part of the merger consideration. The Company accounted for the amount as a reduction of the net proceeds received from Ithaka in return for the issuance of the stock. This treatment was based on the fact that the amount was specifically negotiated by the parties as merger consideration in the merger agreement. There was no service requirement in order to earn the bonus. Due to liquidation preferences in Alsius Medical’s Series A-F redeemable convertible preferred stock and the terms and conditions of the unsecured convertible promissory notes, the allocation of the Merger Shares resulted in the holders of the Bridge Notes and Series F preferred stock receiving their pro rata share, while the holders of the other equity instruments (Series A-E, common stock, and common stock options) did not receive any Merger Shares. The accumulated balance due to the Bridge Note holders was converted at an agreed price of $5.50 per share. This resulted in the recording of additional paid-in capital of $17,036, the amount due to the holders. The Series F redeemable convertible preferred stock was converted at the market price of $5.66 per share at the date of the merger. In addition, due to the underlying terms and conditions of the Series F redeemable convertible preferred stock warrants at the time of the merger (a qualifying sale), all Series F redeemable convertible preferred stock warrants were cancelled, and all existing Alsius Medical equity instruments were cancelled.

Holders of 972,100 shares of Ithaka’s common stock voted against the merger and elected to convert their shares into a pro rata portion of Ithaka’s trust fund. This redeemable common stock was accounted for as mezzanine equity at the time of the merger as it was uncertain whether such amounts would ultimately be redeemed in cash or remain as outstanding common stock. The conversion rights required the holder of the stock to deliver its stock certificate to the Registrant’s transfer agent by August 15, 2007 in order to receive the applicable cash payment. If not executed by August 15, 2007, the stockholder forfeited its right to receive cash payment for the shares. The Registrant redeemed $4,078 (720,600 shares) of the redeemable common stock.

Additionally, as discussed above, as part of consideration paid at the close of the merger, Ithaka agreed to fund bonus payments to the management, employees, two non-employee directors and certain consultants of Alsius Medical totaling $3,000. The merger agreement entitles these individuals to receive an additional amount of up to $2,000 upon the achievement of the above mentioned revenue targets in fiscal years 2007 through 2009 (which are the same revenue targets associated with the issuance of additional Milestone Shares to former Alsius Medical shareholders). The revenue targets for 2007 and 2008 were not achieved and no portion of the bonus was paid for 2007 or 2008. The $3,000 has been accounted for as part of the purchase price. Future payments will be expensed as earned.

The merger was accounted for under the purchase method of accounting as a reverse acquisition, with Alsius Medical as the accounting acquirer. As part of the merger, Ithaka’s common stock of 10,974,100 shares, which consisted of 9,866,392 common shares and 1,107,708 units convertible into common shares, were converted into common stock of Alsius Medical, This resulted in the recording of additional paid-in capital of $73,732. For accounting purposes, the merger has been treated as the equivalent of Alsius Medical issuing stock for the net assets of Ithaka, accompanied by a recapitalization. The net assets of Ithaka are stated at their fair values, which are considered to approximate historical cost, with no goodwill or other intangible assets recorded. The accumulated deficit of Alsius Medical is carried forward after the merger and the operations prior to the merger are those of Alsius Medical. The results of operations of Ithaka are included in the accompanying consolidated financial statements commencing June 22, 2007.

ALSIUS CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except share and per share data)

The purchase price allocation is as follows:

Cash and cash equivalents	$	50,000
Prepaid expenses		98
Accounts payable		(1,082	)
Accrued liabilities		(126	)
Redeemable common stock		(4,078	)
Management bonuses		(3,000	)
Transaction costs		(1,444	)
Net assets acquired	$	40,368

The Milestone Shares and the additional $2,000 in management bonuses have not been included in the above purchase price allocation. If the revenue targets are achieved and the Milestone Shares are issued, the fair value of the consideration will be recorded as an additional capital adjustment.

4. Supplemental Financial Statement Data

Inventories consist of the following:

	December 31, 2008		December 31, 2007
Raw materials	$	3,646	$	3,775
Work-in-process		1,073		1,747
Finished goods		1,091		1,158
	$	5,810	$	6,680

Property and equipment consists of the following:

	December 31, 2008			December 31, 2007

Machinery and equipment	$	1,185		$	1,113
Computer equipment		761			536
Furniture and fixtures		182			186
Leasehold improvements		310			270
		2,438			2,105
Accumulated depreciation and amortization		(1,393	)		(1,071	)
	$	1,045		$	1,034

Depreciation and amortization expense was $326, $191 and $140 for the years ended December 31, 2008, 2007, and 2006, respectively. The amounts of property and equipment under capital leases as of December 31, 2008 and 2007 were $138 and $139 with accumulated amortization of $97 and $55, respectively.

ALSIUS CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except share and per share data)

Accrued liabilities consist of the following:

	December 31, 2008		December 31, 2007
Bonus	$	—	$	480
Inventory		340		23
Vacation		348		320
Warranty		77		107
Interest		30		69
Professional services		229		453
Payroll and related		78		42
Commission		343		232
Royalties		63		38
Deferred revenue		122		60
Other		94		92
	$	1,724	$	1,916

Other income (expense) consists of the following:

	Year Ended December 31,
	2008		2007			2006

Foreign currency remeasurement	$	—	$	(3	)	$	—
Increase in fair value of loan premium liabilities (Note 5)		—		(474	)		(2,156	)
Decrease (increase) in fair value of warrant liabilities		—		512			99
	$	—	$	35		$	(2,057	)

5. Long-Term Debt

The components of long-term debt were as follows:

	December 31, 2008			December 31, 2007
Senior Secured Credit Facility, net of discount of $51 and $164, respectively	$	3,682		$	6,769
Equipment Financing		40			—
		3,722			6,769
Less: current portion		(3,216	)		(3,200	)
Long-term portion	$	506		$	3,569

Senior Secured Credit Facility

On February 22, 2007, and amended on May 11, 2007, the Company entered into a senior secured credit facility with Merrill Lynch Capital (subsequently acquired by GE Capital) consisting of a $10,000 term loan (the “Term Loan”) with an interest rate of one month LIBOR plus 6.50%. Approximately $3,000 of the total amount borrowed was used to repay in full the Company’s secured promissory note issued in May 2005. At December 31, 2008, $3,733 of the Term Loan was outstanding. The Term Loan requires interest only payments for the first six months and interest and principal payments for each month thereafter through February 2010.

In connection with the issuance of the Term Loan in February 2007, the Company issued a warrant to Merrill Lynch Capital with a contractual term of 10 years. The $206 estimated fair value of the warrants issued in February 2007 was recorded as a liability, resulting in a discount to the Term Loan at issuance. The discount is being amortized to interest expense using the effective interest method over the term of the Term Loan.

ALSIUS CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except share and per share data)

In connection with the close of the merger in June 2007, a measurement date for this warrant was achieved, and the warrant issued to Merrill Lynch Capital became exercisable into 43,716 shares of common stock at an exercise price of $5.49 per share. As the warrant is now exercisable into common stock, the fair value of the warrant as of the date of the merger was $215 and reclassified from a liability to equity.

Under the terms of the Term Loan, the Company is prohibited from making certain distributions, including cash dividends. The Company is currently in compliance with such restrictions. Additionally, the Company’s agreements with GE Capital provides GE Capital with a lien on all of the Company’s principal assets other than intellectual property. If the Company defaults on a payment to GE Capital, and the default is not waived, GE Capital can foreclose on the Company’s assets, including seizing the Company’s cash and investment accounts. The Company is currently in compliance with all such restrictions.

Equipment Financing

In April 2008, the Company entered into an equipment financing agreement with a finance company for $51. The agreement requires monthly payments over 36 months.

As of December 31, 2008, principal payments for long-term debt are as follows:

Year ending December 31,
2009	$	3,216
2010		551
2011		6
	$	3,773

6. Authorized Capital Stock

The Company’s authorized capital consists of 1,000,000 shares of $0.0001 par value preferred stock and 75,000,000 shares of $0.0001 par value common stock. The designations, voting and other rights and preferences of the preferred stock may be determined from time to time by the Board of Directors.

The number of shares of common stock of the Company that have been reserved for issuance as of December 31, 2008:

Stock options and restricted stock units (Note 7)			3,904,890
Common stock warrants (Notes 5, 7 and 8)			3,133,714
			7,038,604

7. Stock Options and Restricted Stock Units

1992 Plan

The 1992 Incentive Stock Plan (the “1992 Plan”) provided for the grant of options and stock purchase rights to purchase up to a maximum of 11,000 shares of Alsius Medical’s common stock to employees, officers, consultants and directors. The 1992 Plan included incentive stock options (“ISOs”), nonqualified stock options (“NSOs”) and stock purchase rights. The right to exercise ISOs and NSOs and stock purchase rights vested at a rate in accordance with the individual stock option agreements, which has been immediate to four years for employees and three to four years for non-employees. Options expire within a period of not more than 10 years from the date of grant. ISOs granted to an employee who, at the time the option is granted, owns stock representing more than 10% of the voting power of all classes of stock of the Company, expire within a period of not more than five years from the date of grant. Options expire between thirty and ninety days after termination of employment depending on the circumstances. The 1992 Plan ended in 2002 and no further options have been granted. All options outstanding under the 1992 Plan were cancelled in the merger effective June 21, 2007.

ALSIUS CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except share and per share data)

A summary of option activity under the 1992 Plan is as follows:

	Shares Under Option
	Employee			Non-employee			Total			Weighted Average Exercise Price Per Share
Outstanding at December 31, 2006		5,550			619			6,169			249
Forfeited		(1,276	)		(30	)		(1,306	)		50
Canceled in the merger		(4,274	)		(589	)		(4,863	)		249
Outstanding at December 31, 2007 and 2008		—			—			—			—
Exercisable at December 31, 2007 and 2008		—			—			—			—
Vested and expected to vest as of December 31, 2007 and 2008		—			—			—			—

2004 Plan

The 2004 Stock Incentive Plan (the “2004 Plan”) provided for the grant of options and stock purchase rights to purchase up to a maximum of 2,100,000 shares of Alsius Medical’s common stock to employees, officers, consultants and directors. The 2004 Plan included ISOs, NSOs and stock purchase rights. For ISOs and NSOs, the exercise price per share shall be no less than 110% of the fair market value per share on the date of grant for an individual who, at the time of grant, owns stock representing more than 10% of the voting power of all classes of stock of Alsius Medical. The right to exercise ISOs and NSOs and stock purchase rights vests at a rate in accordance with the individual stock option agreements, which has been immediate to four years for employees, and immediate to three years for non-employees. Options expire within a period of not more than 10 years from the date of grant. ISOs granted to an employee who, at the time the option is granted, owns stock representing more than 10% of the voting power of all classes of stock of Alsius Medical, expire within a period of not more than five years from the date of grant. Options expire between thirty days and six months after termination of employment depending on the circumstances. No stock purchase rights have been granted through the merger. All options outstanding under the 2004 Plan were cancelled in the merger effective June 21, 2007.

A summary of option activity under the 2004 Plan is as follows:

	Shares Under Option
	Employee			Non-employee			Total			Weighted Average Exercise Price Per Share		Weighted Average Contractual Life (Years)

Outstanding at December 31, 2006		1,683,624			164,138			1,847,762			0.30		7.7
Forfeited		(9,877	)		—			(9,877	)		0.30		7.7
Canceled in the merger		(1,673,747	)		(164,138	)		(1,837,885	)		0.30		7.7
Outstanding at December 31, 2007 and 2008		—			—			—			—		—
Exercisable at December 31, 2007 and 2008		—			—			—			—		—

Vested and expected to vest as of December 31, 2007 and 2008		—			—			—			—		—

ALSIUS CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except share and per share data)

2006 Plan

In connection with the Ithaka merger, the Company adopted the new 2006 Equity Incentive Plan (the “2006 Plan”). The 2006 Plan provides for the grant of options and restricted stock units to purchase up to a maximum of 4,159,945 shares of the Company’s common stock to employees, officers, consultants and directors. The number of shares reserved for issuance under the 2006 Plan will be increased on the first day of each fiscal year from 2008 through 2016 to 3% of the fully diluted shares of common stock outstanding on the last day of the immediately preceding fiscal year; provided, however, that the percentage shall be reduced to 2% from and after the time when the Company calls its warrants for redemption (Note 8). The 2006 Plan includes ISOs and NSOs. For ISOs and NSOs, the exercise price per share shall be no less than 110% of the fair market value per share on the date of grant for an individual who, at the time of grant, owns stock representing more than 10% of the voting power of all classes of stock of the Company. The right to exercise ISOs and NSOs vests at a rate in accordance with the individual stock option agreements, which has been immediate to four years for employees, and immediate to three years for non-employees. Options expire within a period of not more than 10 years from the date of grant. ISOs granted to an employee who, at the time the option is granted, owns stock representing more than 10% of the voting power of all classes of stock of the Company, expire within a period of not more than five years from the date of grant. Options expire between thirty days and six months after termination of employment depending on the circumstances.

A summary of option activity under the 2006 Plan is as follows:

	Shares Under Option
	Employee			Non-employee			Total			Weighted Average Exercise Price Per Share		Weighted Average Contractual Life (Years)		Aggregate Intrinsic Value

Outstanding at December 31, 2006		—			—			—		$	—		—		—
Granted		2,742,550			15,000			2,757,550			5.08
Forfeited		(14,700	)		—			(14,700	)		4.89
Exercised		—			—			—			—
Outstanding at December 31, 2007		2,727,850			15,000			2,742,850			5.08		9.51	$	3,786
Granted		465,700			—			465,700			1.27
Exchanged in tender offer for RSUs		(2,037,417	)		(12,000	)		(2,049,417	)		5.00
Forfeited		(614,739	)		—			(614,739	)		5.07
Exercised		—			—			—
Outstanding at December 31, 2008		541,394			3,000			544,394			2.86		9.07		1,310
Exercisable at December 31, 2008		115,449			1,063			116,512			5.08		8.51	$	540
Vested and expected to vest as of December 31, 2008		492,669			3,000			495,669			2.86		9.07	$	1,193

ALSIUS CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except share and per share data)

The following table summarizes stock options outstanding at December 31, 2008:

Outstanding

Exercisable

Range of

Exercise Prices

Number

of Shares

Average

Remaining

Alsius Corp 10-K